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A STUDY OF TREATMENT-BY-SITE INTERACTION IN MULTISITE
CLINICAL TRIALS
Kaleab Zenebe Abebe, PhD
University of Pittsburgh, June 25, 2009
Currently, there is little discussion about methods to explain treatment-by-site interaction
in multisite clinical trials, so investigators are left to explain these differences post-hoc with
no formal statistical tests in the literature. Using mediated moderation techniques, three
significance tests used to detect mediation are extended to the multisite setting. Explicit
power functions are derived and compared.
In the two-site case, the mediated moderation framework is utilized to test two
difference-in-coefficients and one product-of-coefficients type tests. The test in the latter
group is based on the product of two independent standard normal variables, which is a
modified Bessel function of the second kind. Because the alternative distribution does not
have a closed form expression, power is approximated using Gauss-Hermite quadrature. This
test suffers from an inflated type I error, so two modifications are proposed: a combination
of intersection-union and union-intersection tests; and one based on a variance stabilizing
transformation. In addition, a modification of one of the difference-in-coefficients tests is
proposed.
The tests are also extended to deal with multiple sites in the ANOVA and logistic regres-
sion models, and the groundwork has been laid to account for multiple mediators as well.
The contribution of this is a group of formal significance tests for explaining treatment-
by-site interaction in the multisite clinical trial setting. This will serve to inform the design of
future clinical trials by accounting for this site-level variability. The proposed methodology
is illustrated in the analysis of the Treatment of SSRI-Resistant Depression in Adolescents
iii
study conducted across six sites coordinated at the University of Pittsburgh.
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1.0 INTRODUCTION
1.1 STATEMENT OF THE PROBLEM
In power and sample size calculations for randomized clinical trials, the current process
is fairly straightforward. The investigators from different academic and/or industrial sites
come together and agree on a common treatment protocol. They identify an effect size of
the treatment of interest and specify type I and II errors (and therefore, power)a priori. The
investigators then turn to their favorite sample size calculator (or favorite statistician) to
obtain the overall sample size needed (N). Of interest is whether or not N can be obtained at
one particular site, or if several sites are needed. Usually institutional affiliations or previous
collaborations dictate how many sites can be recruited to participate, rather than explicit
methodological considerations. As more sites are involved in the clinical trial, the inherent
differences among them can build up and take a toll on the power to detect treatment effects.
As a result, a treatment-by-site interaction can appear in the analysis stage of the clinical
trial, which can temper the true effect of treatment. Investigators are left to discern the
differences post-hoc.
This issue was recently investigated by Vierron and Giraudeau who incorporated a pre-
specified intraclass correlation (ICC) into the typical sample size equation for a two-way
mixed ANOVA model without interaction [49] . They found that for a fixed overall sample
size, as the ICC and the number of sites varied, the estimated power did not deviate too
much from the nominal power of 0.80. Their recommendation was to avoid recruiting a large
number of sites relative to the overall sample size due to costs associated with more sites.
If the number of patients per site does not cause the power to decrease, then what does?
The intent of this dissertation is to identify those sources of site heterogeneity that do, as well
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as their impact on estimates of treatment effect. Among others, an example is a therapist at a
particular site delivering cognitive behavior therapy in a different manner than a therapist at
another site. By identifying sources at the design stage of a clinical trial, differences leading
to a treatment-by-site interaction can hopefully be minimized. Yet, in order to identify said
sources, one must have an idea of how to tackle the issue of treatment-by-site interaction at
the analysis stage. This will inform the designs of future multisite clinical trials.
1.2 MOTIVATION
The motivation behind this research proposal stems from the meta-analysis done by
Bridge et al. [8] that weighed the efficacy and risk of suicidal ideation in children and ado-
lescents taking antidepressants. The study synthesized the results from 27 placebo-controlled
trials of antidepressants in subjects suffering from major depressive disorder, obsessive com-
pulsive disorder, or non-OCD anxiety. Studies ranged in size from single-site trials of 40
subjects to multisite trials of 396 subjects, with the maximum number of sites being 59.
By using the DerSimonian-Laird random effects model, pooled risk differences in response
were obtained for each of the three disorders. Although there was an increased risk in
suicidal thoughts across all disorders, the risk differences within each disorder group were
not statistically significant. The conclusion was that the benefits outweighed the risks in
each of the three disorders.
Upon examination of the potential moderators of clinical response, the authors found
that the estimated effect size decreased as the number of sites in each study increased. This
finding tempers one of the principal advantages of a multisite clinical trial (as opposed to a
single site) which is that larger sample sizes result in higher power. Dr. David Brent, of the
Department of Psychiatry, posed the problem of understanding
“...the impact of increasing number of sites on power taking into account the increase in
‘noise’ due to differences in assessment and treatment procedure.”
This gave rise to the question of whether explicit sources of site heterogeneity could be identi-
fied at the design stage (such as outcome reliability, patient severity, patient characteristics)
2
as well as their quantitative impact on the degradation of treatment effect.
In the next chapter, we give a summary of multisite clinical trials, including commonly
used methods of analysis. Also, the two primary estimators of treatment effect, weighted
and unweighted, are compared and contrasted in the context of several scenarios that occur
in multisite trials: disparate sample sizes across sites and the presence of treatment-by-site
interaction. Finally, hierarchical linear models are introduced and their properties regarding
sources of site heterogeneity are discussed.
In Chapter 3, the relationship between treatment effect size and the number of sites is
investigated as well as the identification of potential sources of site heterogeneity from the
Treatment of SSRI-Resistant Depression in Adolescents (TORDIA) multisite clinical trial.
In Chapter 4, several statistical methods to identify sources in regression and ANOVA
models are shown using an idea called “mediated moderation” applied to the multisite clinical
trial setting. Three significance tests popular in investigating mediation were extended. For
each, their respective test statistics are described and power analyses are performed. In
addition, the tests are illustrated on the TORDIA dataset.
Multisite mediated moderation (MMM) is extended to the logistic regression models in
Chapter 5. A simulation study to estimate power is conducted, and the significance tests
are applied on the TORDIA dataset.
Finally, the last chapter presents a discussion and lays down the foundation for future
work.
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2.0 LITERATURE REVIEW
2.1 MULTISITE CLINICAL TRIALS
2.1.1 Introduction
Meinert defines a multi-center clinical trial as one that has at least two clinics (or cen-
ters), a common treatment protocol, and a centralized unit to receive and process the study
data [38]. Multisite trials are preferred to their single site counterparts for several reasons,
Kraemer suggests [27]. First, the multisite trial has the ability to recruit many more sub-
jects than the single site trial, resulting in higher power. The time it could take for a single
site trial to accrue the same amount of patients as a corresponding multisite trial could be
substantially longer.
The second advantage is generalizability. Several single site trials can be designed to
address the same question yet yield varying results. This may be due to different patient
characteristics in certain geographic regions or substantially different treatment protocols
between sites. On the other hand, bringing those different patient populations together in
one multisite trial makes it easier to study treatment effects on patients in general.
Finally, multisite trials have the ability to bring together experts with widely varying
viewpoints concerning the treatment protocol. In single site trials, centers that tend toward
a particular philosophy may have results that are affected by that philosophy. For example, if
a single-site psychiatric trial for treatment of depression is based at an academic center that
adheres to the use of selective serotonin re-uptake inhibitors (as opposed to cognitive behav-
ioral therapy), then the resulting effect of treatment may shortchange cognitive behavioral
therapy.
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2.1.2 Model / Analysis
Whereas single-site trials can focus on a single treatment effect, multisite trials have the
added difficulty of dealing with site effects. Despite the fact that the sites are expected to
follow a common protocol, their estimated treatment effects are not guaranteed to be similar.
This is due to site heterogeneity, as will be explained in detail in the next chapter.
The classic analytic approach in multisite studies analysis is to include in the model an
effect for site. For instance, a fixed effects model for comparing a response Yijk between two
treatments across J sites is
Yijk = µ+ τi + ςj + ijk (2.1)
where i = 1, 2, j = 1, ..., J , and k = 1, ..., nij. The usual model constraint is that
2∑
i=1
τi =
J∑
j=1
ςj = 0. The treatment, τi, and site main effects, ςj, are nonrandom and the replication
errors, ijk, are i.i.d. N(0, σ
2) variates. The model assumes that the effect of treatment is
constant across sites [17]. Because each of the sites is expected to follow the common study
protocol and accrue patients independently, the assumption of no interaction is a desirable
one in multisite clinical trials. In fact, the International Conference on Harmonisation (ICH)
E9 guideline on statistical principles strongly recommends the non-interaction model, (2.1),
for analysis [23]. With regard to this, Gallo (2000) states: “Rarely is a trial undertaken with
a clear expectation regarding the nature of different effects expected in different centers.”
[17]
On the other hand, due to differences in underlying patient populations as well as subtle
protocol deviations, the treatment effects can easily differ across sites. Under this assump-
tion, the above model is modified in the following way:
Yijk = µij + ijk = µ+ τi + ςj + γij + ijk (2.2)
where γij is a fixed effect. The usual constraints in addition to that of (2.1) are
2∑
i=1
γij =
J∑
j=1
γij = 0.
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2.1.3 Interaction
The presence of treatment-by-site interaction makes it difficult to interpret the main
effect of treatment. Even trying to detect the phenomenon is difficult because tests for
interaction typically have low power [27, 14, 33, 45, 17, 46, 51]. The reason for this is that
most trials have power only to detect main effects, such as treatment effect, but adequate
power to detect an interaction requires a much larger sample size [10]. Due to this lack
of power, falsely rejecting the hypothesis of no interaction, risks having biased estimates of
main effects [14]. A common approach used by statisticians, although not optimal, is to use
model (2.2) and remove the interaction term when a significance test for interaction results
in a p-value larger than .1 or .2 [45, 17, 51].
2.1.4 Treatment Effect
After choosing the type of model for multisite studies, the most important step is examin-
ing the true effect of treatment, since evaluating this effect is the main reason for conducting
the trial in the first place. For simplicity, suppose that each site has the same number of
subjects taking each of the two treatments (n1j = n2j = nj; n1 = ... = nj). The true treat-
ment effect (or treatment difference) at a particular site j is δj = µ1j − µ2j is estimated by
d¯j = Y¯1j. − Y¯2j. [48]. Then, δ =
∑J
j=1 δj
J
is the true average treatment effect across sites and
is estimated by d¯ =
∑J
j=1 d¯j
J
= Y¯1..− Y¯2... The interpretation of this is quite straightforward.
Although it is simple, the completely balanced case shown above is unrealistic. Since
randomization in multisite trials is done at the site level, it is not uncommon to have nearly
identical sample sizes across treatments, but not across sites. Having unequal number of
subjects per site is more typical in multisite trials [46].
In the case of unequal sample sizes, the use of the above estimator, d¯, raises the question
of whether larger sites add more to the effect of treatment despite being weighted the same as
much smaller sites. Also, in the presence of sample size disparities and/or treatment-by-site
interaction, what type of estimator is most easily interpretable?
Two estimators, introduced by Fleiss (1985), have led to much discussion about how
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best to estimate the overall effect of treatment [14]. The weighted (or type II) estimator is
defined as follows:
d¯w =
J∑
j=1
wj d¯j
J∑
j=1
wj
, (2.3)
where d¯j is described above and wj =
n1jn2j
n1j+n2j
are the weights at each site j. Each weight
function is the harmonic mean of the sample sizes associated with a particular site j. Also,
the weights are inversely proportional to the variance of the response variable, so larger
sites get larger weights. The interpretability of d¯w is clear unless there is treatment-by-site
interaction. This is well illustrated by showing that the underlying parameter estimated by
d¯w differs under models (2.1) and (2.2). Under the full model (2.2),
E(d¯w) =
J∑
j=1
wjE(d¯w)
J∑
j=1
wj
=
J∑
j=1
wjE(Y¯1j. − Y¯2j.)
J∑
j=1
wj
. (2.4)
Since E(Y¯ij.) = µij = µ.. + τi + ςj + γij, we have
E(d¯w) =
J∑
j=1
wj (τ1 + γ1j − τ2 − γ2j)
J∑
j=1
wj
= (τ1 − τ2) +
J∑
j=1
wj (γ1j − γ2j)
J∑
j=1
wj
. (2.5)
As evident from above, the estimate d¯w is unbiased for the true treatment difference when
the treatment-by-site interaction is absent, or when the sample size weights are identical at
each site.
The unweighted (or type III) estimator is:
d¯u =
J∑
j=1
d¯j
J
, (2.6)
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where d¯j is as before. In this case, all sites get equal weight, regardless of sample sizes. Since
d¯u is just the unweighted average across all sites, it is always interpretable – even in the
presence of interaction – because
E(d¯u) =
J∑
j=1
E(d¯u)
J
=
J∑
j=1
(τ1 + γ1j − τ2 − γ2j)
J
= τ1 − τ2, (2.7)
under the usual model restrictions that require
I∑
i=1
γij =
J∑
j=1
γij = 0.
Several authors have attempted to tackle the issue of which estimator to use in which
cases, namely disparate sample sizes across sites and treatment-by-site interaction. First,
for unequal sample sizes, the consensus is that the weighted estimator is superior to the
unweighted in the sense that the variance of d¯u is always at least as big as the variance of
d¯w [33, 45, 17, 46].
A commonly proposed solution to the problem of disparate sample sizes is to pool smaller
centers into a larger one (usually until a maximum sample size per center is reached), which
is explained in detail in Lin, Gallo, and Worthington [33, 17, 51]. This has been met with
criticism by some authors who argue that it results in loss of power as well as the potential
introduction of bias (especially in the unweighted case) [33, 17]. When combining small
centers, the assumption that they are similar to each other is not guaranteed.
Secondly, others say that treatment-by-site interaction eliminates d¯w as a possibility due
to the lack of interpretability described above [45, 46]. On the other hand, Gallo claimed
that as long as there was no systematic relationship between site sample size and within-site
effect, the parameters that d¯w and d¯u estimate are identical [17].
2.1.5 Fixed versus Random Sites
The issue of whether sites should be modeled as fixed or random effects is an intriguing
one that deserves discussion. According to the textbook definition [31], a factor should
be considered random if interest in its effect on the response variable extends beyond the
factor levels used in the analysis. On the other hand, if the factor levels are the only levels
of interest, then the factor is clearly fixed. Some factors, such as gender, are inherently
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fixed. However, there seems to be agreement that the effect of site should be considered
fixed [46, 51]. Among the reasons given are that sites are not usually chosen in a “random”
manner, but rather based on previous collaborations. For example, academic institutions
that have worked together on previous clinical trials usually develop good relationships which
facilitate finding sites for future studies.
In the case of random site effects, (2.1) and (2.2) are modified in the following way:
Yijk = µ+ τi + Sj + ijk (2.8)
and
Yijk = µ+ τi + Sj +Gij + ijk, (2.9)
where Sj ∼iid N(0, σ2S) and mutually independent of Gij ∼iid N(0, σ2G).
Senn (1998) gives a detailed overview of both sides of the random versus fixed argument
[46]. Some advantages of the fixed approach include the following. First, there is better
precision of the estimate of effect because the variance is smaller. Second, it is the only
realistic option in the presence of very few sites. An example of this would be studies of very
rare diseases, where it may be that only a handful of sites specialize in it. Third, to regard
sites as random is unrealistic due to the fact that actual random sampling rarely occurs.
In defense of the random approach, the purpose of developing treatments is to say some-
thing about their effects on patients in general. By adding the site variability, the scope
of prediction is broadened to include patients from different geographic regions. Second, if
interest is about a given site, the fixed approach leaves little alternative but to use the results
from that site only.
Another interesting point is whether it is appropriate to assume that random effects follow
a normal distribution. If the underlying distribution of the effect is highly skewed, then bias
may occur in the estimation of the effect [2]. Ways to remedy this include assuming a skew-
normal or skew-t distribution, which is beyond the scope of this proposal but is discussed in
Azzalini and Capitanio [4, 5].
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2.1.6 Hierarchical Linear Models
There are a number of data structures that are naturally hierarchical in their organiza-
tion. In educational studies, students may be nested within a class with the same teacher,
the teachers in turn nested in particular schools, and so on. In longitudinal studies, a sub-
ject’s measurements over time are nested within that subject. Multisite clinical trials are no
exception to this. Because randomization is conducted at the level of the individual sites,
patients are expected to be more closely related to those within their site.
Raudenbush and Bryk give an account of the theory and applications of hierarchical
linear models (HLMs) [41]. which are able to model at the level of the study sites as well
as the level of the subjects within them. Three main features of HLMs that the authors
emphasize are as follows. First, hierarchical linear models allow improved estimation of the
effects at the subject-level. This is due, in part, to the fact that individual sites have their own
separate regression equations that “borrow strength” from other sites with similar estimates.
Second, besides investigating effects at a particular level, HLMs allow the examination of
effects across levels. In multisite trials, this can be likened to the effect of treatment across
sites, or treatment-by-site interaction. Third, the use of variance-covariance components
facilitates estimation in unbalanced designs.
Examples of HLMs are one-way random effects AN(C)OVA, means-as-outcomes regres-
sion, random coefficients regression, and coefficients-as-outcomes regression. The rest of this
section will restrict its attention to the latter two.
The random coefficients model is set up as follows [42]. The subject-level model is
Yjk = β0j + β1jXjk + rjk (2.10)
where j = 1, ..., J , k = 1, ..., nj, and rjk are i.i.d. N(0, σ
2). Notice that the subscript i has
been suppressed. Xjk is a treatment contrast for subject k in site j taking a value of 1 for
treatment and -1 for control subjects. The intercept β0j represents the mean response for
site j, while the slope β1j is the effect due to a subject’s particular treatment. The site-level
model is
β0j = α00 + α0j (2.11)
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β1j = α10 + α1j (2.12)
where α00 and α10 are the grand mean and average treatment effect, respectively. α0j and
α1j are random effects, independent of rjk, that are distributed as α0j
α1j
 ∼iid N
 0
0
 ,
 η00 η01
η01 η11
 .
As can be seen above, both the intercept and slope have their own respective random effects
which account for the variability in the mean response and mean treatment effect across sites.
In addition, the parameter η01 denotes the covariance between the mean and the treatment
effect at a particular site. When (2.10), (2.11), and (2.12) are combined, the resulting full
model is
Yjk = α00 + α10Xjk + α0j + α1jXjk + rjk. (2.13)
The variance of a particular observation is
Var(Yjk) = σ
2
Y = η00 + η11 + 2Xjkη01 + σ
2, (2.14)
which depends on the treatment. The covariance between two different observations in the
same site and taking the same treatment is denoted by
Cov(Yjk, Yjk′) = σkk′ = η00 +XjkXjk′η11 = η00 + η11. (2.15)
For two different observations that also differ in treatment (denoted by the missing subscript
i), (2.15) becomes
Cov(Yjk, Yjk′) = σii′ = η00 − η11. (2.16)
Finally, the covariance between two observations neither from the same site nor taking the
same treatment is
Cov(Yj′k, Yjk′) = 0. (2.17)
By adding a subscript for treatment (i = 1, 2), (2.13) is nearly identical to the full
mixed-effects model, (2.9).
Yijk = α00 + α10i + α0j + α1ij + rijk. (2.18)
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The main difference between the two models is that in (2.18), α0j and α1ij are independent
of each other for a particular treatment, i.
The coefficients-as-outcomes model takes one step further and adds site-level predictors,
Wj, to model said variability. The site-level equations become
β0j = α00 + α01Wj + α0j (2.19)
β1j = α10 + α11Wj + α1j. (2.20)
One important thing to notice is the fact that the predictor is used in both the intercept and
slope models. Raudenbush and Liu point out that due to the correlated nature of the errors,
α0j and α1j, failure to specify the errors in the intercept model may lead to an inaccurate
estimate of the predictor’s contribution to the treatment effect. The authors also note that
large treatment-by-site variance, η211, signals the need to add site-level predictors to model
the extra variation [42].
There are three main issues in multilevel analysis that HLMs deal with: 1) aggregation
bias, 2) misestimation of standard errors, and 3) heterogeneity of regression [41]. The first
issue occurs when the relationship between variables takes on different meanings at different
levels. For example, two variables may be highly correlated in one direction among an
unnested group of subjects. When nesting occurs and mean values of the variables are
computed, the correlation could be in the opposite direction or diminished entirely. This is
also known as the ecological fallacy [44]. Hierarchical models address this by decomposing
the full model to show relationships within and across all levels.
Another common problem in multilevel analysis is not taking into account the correlated
(dependent) nature of the grouped observations. By including a random effect for each site,
HLMs use this added information when estimating the standard errors [42].
The third problem, heterogeneity of regression, exists when relationships between pre-
dictors and outcomes vary across sites. This is dealt with by estimating separate sets of
regression coefficients for each site. The variability at the second level can then be accounted
for by other predictors [42].
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3.0 SOURCES OF SITE HETEROGENEITY
The previous chapter outlined some of the common methods of analyzing a multisite
clinical trial as well as the issues statisticians are likely to face while doing so. The purpose
of Chapter 3 is to investigate the effect that the number of sites chosen has on the effect of
treatment. If there is no relationship, then there are other sources at work that need to be
identified.
3.1 RELATIONSHIP BETWEEN TREATMENT EFFECT SIZE AND THE
NUMBER OF SITES
In investigating the relationship between effect size of treatment and the number of sites,
4 different clinical trials were simulated with 200 participants each. The trials varied from
one another by the number of sites each had, ranging from 2 sites of 100 each to 10 sites of
20 participants. Within each site, the number of treatment and control subjects were equal,
making the trials completely balanced (n1j = n2j = n for all sites, j = 1, ..., J).
In the initial simulation, we considered a continuous outcome variable, Yijk, coming from
the following distribution
Yijk ∼ N(µ.. + τi + ςj, σ2), (3.1)
where µ, τi, and σ
2 denote the overall mean, treatment effect, and error variance respectively.
While µ was arbitrarily chosen to be 0, the values of τ and σ were chosen such that they
would yield a treatment effect size of 0.4, which was close to the weighted average of effect
sizes in the Bridge et al. meta-analysis [8]. The site effects ς1, ..., ςJ were generated from
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a N(0, 0.5) distribution subject to the constraint
J∑
j=1
ςj = 0. This was accomplished by
obtaining ς1, ..., ςJ−1 and then setting ςJ =
J−1∑
j=1
−ςj. The 0.5 variance was arbitrarily chosen
to represent noise.
The simulated data were then fit using the following one-way ANOVA comparing treat-
ment and placebo:
Yik = µ.. + τi + ik. (3.2)
For each site number iteration, the mean of 1000 effect sizes was computed using Hedges’s
g:
ĝ =
Y¯1.. − Y¯2..√
(MSE)
, (3.3)
where the pooled standard deviation is the square root of the mean square error obtained
from the above model:
MSE =
2∑
i=1
J∑
j=1
n∑
k=1
(Yijk − Y¯i..)2
2Jn− 2 =
2∑
i=1
(Jn− 1)s2i
2Jn− 2 . (3.4)
Because the sample sizes for each treatment-site combination are equal, (3.4) reduces to
MSE =
s21 + s
2
2
2
, (3.5)
which is nothing more than the average variance across treatment and placebo.
Regarding the MSE, Kraemer et al. states that the power to detect treatment effects
is inversely related to the number of sites, for a fixed sample size N [29]. This is only the
case when the MSE from a two-way ANOVA with treatment and site (and possibly, their
interaction) is used. This would be a misspecification because the standard deviation should
be that of the raw outcome scores [37, 19]. For instance McGaw and Glass give an example
of a study comparing treatment and control conditions (factor A) across gender (factor B)
[37]. The model is a two-way ANOVA with both main effects as well as their interaction
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(factor AB). To calculate the appropriate effect size in this example, the denominator should
be
σˆ =
√
SSB + SSAB + SSE
dfB + dfAB + dfE
. (3.6)
Because SSB + SSAB + SSE and dfB + dfAB + dfE are equivalent to the SSE and dfE,
respectively, from a balanced one-way ANOVA with only an effect for treatment suggests
that the denominator used in (3.3) is correct.
Returning to the simulation, the mean effect size was then plotted against the number of
sites, which did not reveal any relationship between the two. Since the MSE is distributed
as
σ2
2Jn− 2χ
2
2Jn−2 and Y¯1.. − Y¯2.. is independent of
√
MSE, (3.3) can be rewritten as
E(ĝ) = E
(
Y¯1.. − Y¯2..
σ
√
σ2
MSE
)
=
µ1 − µ2
σ
E
(√
df
χ2df
)
, (3.7)
with degrees of freedom df = 2Jn− 2. It can be shown that the expectation of the random
variable is equivalent to C(p), where
C(p) =
√
pΓ
(
p−1
2
)
√
2Γ
(
p
2
) . (3.8)
In fact, Hedges and Olkin showed that the estimator for Hedges’s g was upwardly biased
without the correction factor C(p) [20, 11]. So, (3.7) reduces to
E(ĝ) =
µ1 − µ2
σ
C(df). (3.9)
While this is indeed a function of the degrees of freedom (and hence, the number of sites
J), it is a constant because the error degrees of freedom do not change because the overall
sample size is N = 2Jn = 200. Returning to Kraemer’s statement in the previous paragraph,
using the MSE from the two-way ANOVA changes df from N −2 to N −2J . So in this case,
C(df) is in fact a decreasing function of the number of sites, although the decrease is very
slow.
This analytical result suggests that there is nothing inherently heterogeneous about the
number of sites chosen. Rather, specific sources of site heterogeneity are solely responsible
for the degradation of treatment effect.
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3.2 TREATMENT OF SSRI-RESISTANT DEPRESSION IN
ADOLESCENTS
As was shown in the previous section, there is nothing inherently heterogeneous about
the number of sites chosen in multisite clinical trial. Therefore, there are other sources to
blame. A motivating example is the following study.
The Treatment of SSRI-Resistant Depression In Adolescents (TORDIA) clinical trial
was an NIMH funded multisite study that sought to evaluate the efficacy of four treatment
strategies in depressed youths [7]. A sample of 334 patients, across 6 sites, with major
depressive disorder who were not responding to an initial 2-month selective serotonin re-
uptake inhibitor (SSRI) treatment were randomized to one of the following regimens
1. switch to a second, different SSRI (paroxetine, citalopram, or fluoxetine),
2. switch to a different SSRI plus cognitive behavior therapy (CBT),
3. switch to venlafaxine, or
4. switch to venlafaxine plus CBT.
The primary dichotomous outcome, clinical response, was defined as the combination of
the Clinical Global Impressions score ≤ 2 and a change in the Children’s Depression Rating
Scale-Revised of ≥ 50%. CBT plus medication (CBT-MED) showed a higher rate of response
than medication (MED) alone (54.8% vs. 40.5%, p=0.009). On the other hand, there
were no differences between medication response rates regardless of CBT use (48.2% vs.
47.0%, p=0.83). In addition, the effect of CBT-MED treatment versus MED alone was
heterogeneous across the sites, ranging from a 35.3% difference favoring MED to a 45.0%
difference favoring CBT-MED.
This finding led to a subsequent paper by Spirito et al. which investigated potential
causes for this treatment-by-site interaction [47]. The paper discussed two potential causes
of site heterogeneity: participant clinical characteristics, and treatment protocol consistency.
The process of identifying these causes was straightforward. The authors first examined
whether particular variables were related to site. If found to be significant, those variables
were examined to see if they were significant predictors of the response variable.
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In the case of clinical characteristics, the stratification variable that measured suicidality
(BDI item 9) differed across sites as well as being significantly related to outcome. In addi-
tion, three of the variables measured at baseline that were significant across sites were also
related to outcome: duration of depression, hopelessness, and family conflict. This implies
that baseline clinical characteristics are a potential source of site heterogeneity. A recursive
partitioning method was then used to determine optimal subgroups where site variability
was minimal [26]. Subjects with low hopelessness and low family conflict comprised the
optimal subgroup, which had a clinical response rate of 67.8% compared with 47.6% from
the original 334 subjects. In addition, the treatment-by-site interaction from above didn’t
exist in this subgroup. Conversely, subjects with high family conflict and high hopelessness
scores had a clinical response rate of 37.0%. Finally, there was a significant imbalance of the
number of subjects from the optimal subgroup across the six sites in the MED-only group.
This imbalance was not present in the CBT-MED group.
With regard to treatment protocol consistency, several of the variables included fidelity
to treatment, ancillary pharmacotherapy and protocol attrition. Treatment fidelity refers
to either fidelity to therapy or fidelity to medication. The former was measured by the
Cognitive Therapy Rating Scale (CTRS), which differed across sites but was not related to
outcome. The same held for the Pharmacotherapy Rating Scale (PTRS), which measured
medication therapy.
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4.0 IDENTIFYING SOURCES OF SITE HETEROGENEITY
4.1 BACKGROUND
As was mentioned in the introduction, when the effect of treatment differs across sites
(i.e. treatment-by-site interaction), the investigators are left to explain the differences post-
hoc. Currently, there is little discussion of the impact of these differences on clinical trials
[47]. In addition, the only publication to date that attempts to explain the methodology of
identifying sources of site heterogeneity is Spirito et al [47].
The process of identification of site differences involves two phenomena: moderation
and mediation (see Kraemer et al. [28], Aiken & West [3], and Baron and Kenny [6]). A
moderator is a baseline variable, uncorrelated with treatment, that identifies subgroups of
patients who have different effect sizes [30]. In the case of a continuous moderator, the effect
size of a particular treatment is a function of the moderator variable. For example, consider
the following equation where there are two levels of treatment, τ = ±1; an outcome, y; and
a moderator variable, mo:
y = β0 + β1τ + β2mo+ β3(τ ∗mo) + . (4.1)
Showing that the coefficient for the interaction term is significant is sufficient to demonstrate
moderation. On the other hand, there are a set of causal relationships that must be shown in
order to demonstrate mediation. First, the treatment must significantly predict the outcome.
Second, a mediator must be significantly predicted by treatment. Third, it must significantly
predict outcome after accounting for treatment. The result is a change in the relationship
between the treatment and outcome [6]. Consider the basic case where there are two levels
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of treatment, τ = ±1; an outcome, y; and a mediator, m. There are 3 equations involved in
the testing of mediation in this scenario:
y = β00 + β01τ + 0 (4.2)
m = β10 + β11τ + 1 (4.3)
y = α00 + α01τ + α12m+ 2 (4.4)
where the i are Gaussian with mean 0, and variance σ
2
i . Equation 4.2 shows the direct
effect of the treatment on the response (β01). Equation 4.3 shows the relationship between
the mediator and treatment (β11). Finally, the residual effect of treatment on response, after
accounting for the effect of the mediator, is shown in equation (α01) 4.4. This is shown
graphically in Figure 1 as a path diagram.
These relationships can be written in terms of the joint distributions of y and m. y
m
 ∼ N

 β00 + β01τ
β10 + β11τ
 ,
 σ20 σ01
σ01 σ
2
1

The final equation is based on the conditional distribution of y given τ and m:
(y|m, τ) ∼ N
(
β00 + β01τ +
σ01
σ21
(m− β10 − β11τ) , σ20 −
σ201
σ21
)
,
and the conditional mean can be rewritten as
E(y|m, τ) =
(
β00 − σ01
σ21
β10
)
+
(
β01 − σ01
σ21
β11
)
τ +
σ01
σ21
m
= α00 + α01τ + α12m. (4.5)
Of course there are redundancies, so the parameters are constrained. For instance,
β01 − α01 = σ01
σ21
β11 = α12β11. (4.6)
In the context of the path diagram, (4.6) says that the difference between the direct and
residual effect of treatment on response is equivalent to the product of the two indirect
paths. The significance test for mediation, according to Baron & Kenny [6] is made up of
three separate tests conducted in succession:
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Figure 1: Mediation Path Diagram
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• H0 : β01 = 0 with test statistic t∗ = b01
σˆb01
∼ tn−2,
• H0 : β11 = 0 with test statistic t∗ = b11
σˆb11
∼ tn−2,
• H0 : α12 = 0 with test statistic t∗ = a12
σˆa12
∼ tn−3,
where n is the sample size. So, if each of the above hypothesis tests result in significance,
then mediation exists. [6].
While the testing of moderation is relatively straightforward [28], there has been much
discussion on how best to test mediation. MacKinnon et al. used simulation to compare
14 different significance tests (including Baron and Kenny’s approach above) for mediation
grouped into three types: causal steps, difference-in-coefficients, and product-of-coefficients
[35]. The authors concluded that widely used causal methods, such as those proposed by
Judd and Kenny [25] and Baron and Kenny [6], had low power. The best causal steps test
was the following significance tests proposed by MacKinnon et al.:
• H0 : β11 = 0 with test statistic t∗b =
b11
σˆb11
∼ tn−2,
• H0 : α12 = 0 with test statistics t∗a =
a12
σˆa12
∼ tn−3,
where n is the sample size. In the difference-in-coefficients group, the following test proposed
by Freedman and Schatzkin had the greatest power and most accurate type I error: [16]
• H0 : β01 − α01 = 0 with test statistic
t∗ =
b01 − a01√
σˆ2b01 + σˆ
2
a01
− 2σˆb01σˆa01
√
1− ρˆ2τm
∼ tn−2
where ρˆ2τm is the correlation between the mediator and treatment. In the last group of tests,
product-of-coefficients, a test introduced by MacKinnon et al. [35] was superior with regard
to power:
• H0 : β11α12 = 0 with test statistic w∗ = b11
σˆb11
a12
σˆa12
, a product of two standard normals
under H0.
While the aforementioned gives good insight into how best to deal with moderation and
mediation separately, site heterogeneity in multisite clinical trials involves dealing with both
simultaneously. For instance, moderation involves differing treatment effects across sites. In
other words, the effect of treatment differs as you move across the levels of site. Moreover,
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site moderating treatment is equivalent to treatment moderating site (i.e. site effects differ
by treatment regimen), so the two concepts are interchangeable.
On the other hand, mediation involves an outside variable influencing the relationship
between an independent variable and the response. For example, exercise has been shown to
be a significant predictor of glucose level in women who are at risk for diabetes [50]. However,
after adjusting for BMI, the association is still significant yet reduced. The obvious reason
is that women who exercise more tend to have a lower BMI, which is also related to glucose
level. Here, BMI is mediating the relationship between glucose level and exercise. Therefore,
returning to the context of multisite clinical trials, the main objective in identifying sources
of site heterogeneity is to pinpoint particular variables that mediate the moderation of site.
Muller et al. [39] describes the methodology of “moderated mediation” and “mediated
moderation”, with the latter being of interest here. Mediated moderation occurs when an
underlying mediation process is responsible for the overall moderation that exists; and by
accounting for that process, the magnitude of moderation is reduced [39]. The previous basic
mediation equations ((4.2), (4.3), and (4.4)) can be extended to a two-site scenario in the
following way:
y = β00 + β01τ + β02s+ β03(τ ∗ s) + 0 (4.7)
m = β10 + β11τ + β12s+ β13(τ ∗ s) + 1 (4.8)
y = α00 + α01τ + α02s+ α03(τ ∗ s) + α12m+ 2, (4.9)
where s = ±1 is the effect of site. In terms of joint and conditional distributions,
 y
m
 ∼ N

 β00 + β01τ + β02s+ β03(τ ∗ s)
β10 + β11τ + β12s+ β13(τ ∗ s)
 ,
 σ20 σ01
σ01 σ
2
1
 ,
and
(y|m, τ, s) ∼ N
(
µy|m,τ,s, σ20 −
σ201
σ21
)
,
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where the conditional mean is
µy|m,τ,s = β00 + β01τ + β02s+ β03(τ ∗ s) + σ01
σ21
(m− β10 − β11τ − β12s− β13(τ ∗ s))
=
[
β00 − σ01
σ21
β10 + β01τ − σ01
σ21
β11τ
]
+
[
β02 − σ01
σ21
β12 + β03τ − σ01
σ21
β13τ
]
s
+
σ01
σ21
m
= (α00 + α01τ) + (α02 + α03τ)s+ α12m (4.10)
One thing to note is that Muller et al. allowed the partial effect of the mediator to be
moderated, which added another term to (4.9) [39]. This is not a necessary condition for
mediated moderation to hold, and we will assume that this partial effect is not moderated
(see Appendix A for details). The direct effect of site, which is a function of treatment, is
β02 + β03τ , and the residual effect is α02 + α03τ . Just as in the basic mediator setup, the
following identities hold:
(β02 + β03τ)− (α02 + α03τ) = (β12 + β13τ) ∗ (α12) (4.11)
β03 − α03 = β13α12. (4.12)
According to Muller et al., mediated moderation can only occur when 1) overall moder-
ation exists (β03 6= 0), 2) both paths are statistically significant, and 3) there a decrease in
moderation after adjusting for the mediator [39]. In the context of multisite clinical trials
where a treatment-by-site interaction is detected, the first criteria is already met. Also, the
decrease in moderation can be measured by the magnitude of the interaction parameter(s).
We will refer to the extension of mediated moderation to multisite clinical trials as “multisite
mediated moderation” (MMM) from here on.
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Figure 2: Multisite Mediated Moderation Path Diagram: 1 Mediator
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4.2 MMM IN THE 2-SITE CASE
4.2.1 Significance Testing with 1 Mediator
Three significance tests were selected from MacKinnon et al. in order to see how the MMM
idea could be applied. From the difference-in-coefficients group, the Freedman & Schatzkin
and Olkin & Finn tests were chosen, while the Product of Standardized Coefficients test
was chosen from the product-of-coefficients group. For each of the significance tests, their
test statistics were extended to the multisite case and their power functions were derived.
All significance tests throughout this dissertation were two-sided as well as based on large
sample approximations.
4.2.1.1 Freedman & Schatzkin Test For the first test, by Freedman and Schatzkin,
the null hypothesis, test statistic, and power function are as follows: H0 : β03−α03 = 0 with
test statistic t∗ =
b03 − a03√
σˆ2
∼ tn−4 where
σˆ2 = σˆ2b03 + σˆ
2
a03
− 2σˆb03σˆa03
√
1−R2
=
MSE0
n
+
MSE2
(1−R2)n − 2
√
MSE0
√
MSE2
n
. (4.13)
Above MSEi are the estimates of the corresponding errors in equations (4.7), (4.8), and
(4.9), and R2 is the multiple correlation squared when the interaction τs is regressed on τ ,
s, m, and mτ . The power function is
power = P
(|t∗| > tn−4,1−α/2‖H1) = P (|tn−4,ψ| > tn−4,1−α/2) (4.14)
where tn−4,ψ is a non-central t distribution with non-centrality parameter ψ =
∆√
σ2
for the
alternative value ∆ = β03 − α03.
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4.2.1.2 Olkin & Finn Test The Olkin and Finn test is based on the difference between
ρys(τ), the point-biserial correlation between outcome and site at a particular level of treat-
ment, and ρys.m(τ), the partial point-biserial correlation between the two after accounting
for the effect of the mediator. H0 : {ρys(τ) − ρys.m(τ) = 0; τ = T,C} with joint test statis-
tics z∗T =
fT (r)√
σˆ2T
and z∗C =
fC(r)√
σˆ2C
, where fi(r) = rysi − rysi − rymirsmi√
1− r2ymi
√
1− r2smi
for treatment
and control, respectively. We assumed large samples and the multivariate delta method to
obtain σˆi
2 = aiΦia
′
i, where ai =
(
∂fi(r)
∂rysi
,
∂fi(r)
∂rymi
,
∂fi(r)
∂rsmi
)
and Φi is the covariance
matrix of the zero-order correlations described in Olkin and Siotani [40]. By definition, this
is a union-intersection test, so the null hypothesis is that there is no difference between cor-
relations in both the treatment and control groups. The alternative hypothesis states that
there is a significant difference between correlations in at least one of the groups [9]. On
the other hand, the hypotheses of a intersection-union test would be defined as follows. The
null hypothesis is that there is no difference between correlations in at least one of the two
treatment groups, while the alternative states that there is a significant difference in both
groups [9].
The critical values, u1 and u2, are chosen with type I error such that
α = PH0 (|z∗T | > u1) + PH0 (|z∗C | > u2)− PH0 (|z∗T | > u1)PH0 (|z∗C | > u2) . (4.15)
If u1 and u2 are both chosen to be z1−α0/2 where α0 = 0.0253, this yields a test of size 0.05.
So, the power is
power = P
|z| > z.98735 − ∆T√
σˆ2T
+ P
|z| > z.98735 − ∆C√
σˆ2C

−P
|z| > z.98735 − ∆T√
σˆ2T
P
|z| > z.98735 − ∆C√
σˆ2C
 . (4.16)
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4.2.1.3 Product of Standardized Coefficients Test Finally, the details of the prod-
uct of standardized coefficients (PSC) test by MacKinnon et al are: H0 : {β(τ)α = 0; τ =
T,C} where β(τ) = β12 + β13τ and α = α12 are independent with respective test statistics
w∗T =
bT
σˆbT
a
σˆa
and w∗C =
bC
σˆbC
a
σˆa
. The standard errors, σˆbi and σˆa, can be explicitly written as√
2MSE1
n
and
√√√√ MSE2
(n− 1)s2m
(
1−R2(m)
) , respectively, where R2(m) is the multiple correlation
from (4.8). Craig showed that the product of two standard normals has pdf pi−1K0(|x|),
where K0(|x|) is a modified Bessel function of the second kind with order zero, and provided
tables for critical values [12]. Therefore critical values, u1 and u2, are chosen with type I
error such that
α = PH0 (|w∗T | > u1) + PH0 (|w∗C | > u2)− PH0 (|w∗T | > u1)PH0 (|w∗C | > u2) . (4.17)
The power function follows
power = PH1
(|w∗T | > d1−α0/2)+ PH1 (|w∗C | > d1−α0/2)
−PH1
(|w∗T | > d1−α0/2)PH1 (|w∗C | > d1−α0/2) , (4.18)
where d1−α0/2 is the appropriate critical value and α0 is the significance level chosen to
achieve an overall size α test. Under the alternative hypothesis, |w∗i | is distributed as the
product of two independent normal random variables with non-null means and unit variance.
Closed form expressions are not available for this distribution, so we used Gauss-Hermite
quadrature with 32 knots to approximate the probability function (see Appendix B) [1].
A difficulty arises such that the test statistics are distributed as modified Bessel functions
under the null hypothesis only when both α and β are zero. As a consequence, the true type I
error will be inflated. Craig derived the mean and variance of the product of two independent
normal variables divided by their respective standard deviations [12]:
E
(
ba
σβσα
)
=
βα
σβσα
(4.19)
Var
(
ba
σβσα
)
=
β2
σ2β
+
α2
σ2α
+ 1. (4.20)
27
It should be evident from the above central moments that as one of the means grows, the
variability of the product also grows. While the sample mean is still symmetric around the
origin, the tails become fatter thus increasing the type I error [12]. The simulation study of
the product of standardized coefficients in MacKinnon et al. validated this [35].
4.2.1.4 Combination Test One remedy is to rewrite the product of coefficients hypoth-
esis as a combination of intersection-union and union-intersection tests (referred to from now
on as the combo test). The null hypothesis would be that at least one of the indirect paths
is non-significant in both treatment and control. The alternative is that both indirect paths
are significant in at least one of the treatment groups. H0 : {β(τ) = 0 or α = 0; τ = T,C}
with test statistics t∗bi =
bi
σˆbi
and t∗a =
a
σˆa
for i = T,C, and where σˆbi and σˆa are described
previously. Then, critical values, ui, with an overall type I error can be chosen such that
α = PH0 (|t∗bT | > u1)PH0 (|t∗a| > u2) + PH0 (|t∗bC | > u3)PH0 (|t∗a| > u4)
−PH0 (|t∗bT | > u1)PH0 (|t∗a| > u2)PH0 (|t∗bC | > u3)PH0 (|t∗a| > u4) . (4.21)
In the worst case scenario that two of the parameters, say βT and βC , have non-null means,
then the overall type I error rate is still determined by the choice of u2 and u4 [9]. Therefore,
all critical values should be chosen to be tdf,0.98735 in order to achieve an overall type I error
rate of 0.05, where df = n− 5 for u2 and u4 and df = n− 4 for u1 and u3.
4.2.1.5 Variance Stabilizing Transformation Test Another modification of the
product of standardized coefficients test is to use a variance stabilizing transformation [32].
Since we know
√
n
(
bi
σ1
− βi
σ1
)
=⇒ N(0, 1) and √n
(
a
σ2
− α
σ2
)
=⇒ N(0, 1),
where σ1 = 2σ and σ2 =
√√√√ nσ2
(n− 1)s2m
(
1−R2(m)
) , then by the multivariate delta method
[32]
√
n
(
bia
σ1σ2
− βiα
σ1σ2
)
=⇒ N
(
0,
α2
σ22
+
β2i
σ21
)
.
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So, a variance stabilizing transformation is a function, f(θ), that satisfies
f ′(θ) =
c√
τ 2(θ)
, (4.22)
where τ 2(θ) is the variance as a function of θ. If we let θ =
βiα
σ1σ2
, then we can reparametrize
and let
θ
w
=
βi
σ1
and w =
α
σ2
. Now, τ 2(θ) =
θ2
w2
+ w2 and it is evident that the variance
is proportional to the square of the mean. At first glance, this would suggest a logarithmic
transformation [21]. If we set w = 1 and integrate both sides of equation 4.22 with c = 1,
we get the variance stabilizing function to be
f(θ) = sinh−1(θ) = ln
(
θ +
√
1 + θ2
)
. (4.23)
Therefore,
√
n
(
f(θˆ)− f(θ)
)
=⇒ N(0, 1), (4.24)
where θˆ =
bia
σˆ1σˆ2
. Since we parametrized w = 1, then we can fix α = σ2 and the hypothesis
test becomes H0 : {θ(τ) = 0; τ = T,C} with test statistics z∗i =
√
n
{
f
(
θˆ
)
− f (θ)
}
where
i = T,C is defined above.
In order to check the type I error and power of the VST test, we conducted a simulation
study with the following steps.
• One million replicates of the following random variables were drawn: a ∼ N
(
α,
σ22
n
)
and bi ∼ N
(
βi,
σ21
n
)
where α = σ2 is set.
• For each replicate, θˆ = bia
σˆ1σˆ2
and z∗ =
√
n
{
f
(
θˆ
)
− f (θ)
}
are calculated.
• The true type I error and power are estimated as the number of |z|’s that exceed the
critical value under the null or alternative, respectively.
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4.2.1.6 d Test A fundamental issue regarding the tests that fall into the difference-in-
coefficients category is the assumption of normality in the estimates of the coefficients. If we
take a look at the basic mediator setup, we can see that β01 and α01 are estimated by
b01 =
∑n
i=1 yiτi
n
(4.25)
a01 =
1
n
n∑
i=1
yiτi − b11
∑n
i=1(yi − y¯)(mi − m¯)
(n− 1)σˆ21
. (4.26)
If we call the difference dˆ = b01 − a01, then conditional on m and τ , the distribution of dˆ is
Gaussian with the following mean and variance
E(dˆ|m, τ) = b11
∑n
i=1 E(yi − y¯)(mi − m¯)
(n− 1)σˆ21
=
b11β01
∑n
i=1miτi
(n− 1)σˆ21
(4.27)
Var(dˆ|m, τ) =
[
b11
(n− 1)σˆ21
]2 n∑
i=1
Var(yi − y¯)(mi − m¯)2 = b
2
11σ
2
0s
2
m
(n− 1)(σˆ21)2
. (4.28)
Due to the equality (4.6), a significance test of H0 : d = 0 should be equivalent (or nearly
equivalent) to the Freedman-Schatzkin test.
Since m is random, our interest should be on the unconditional distribution of dˆ. The
reason for this is that the unconditional variance is always larger than the conditional.
Therefore, many of the analyses that treat the mediator as a fixed quantity when it is indeed
random can severely underestimate the variance, which can overestimate the power.
The unconditional mean and variance of dˆ are
E(dˆ) = E
[
E(dˆ|m, τ)
]
=
β01
n− 1E
[
(
∑n
i=1miτi)
2
σˆ21
]
(4.29)
Var(dˆ) = Var
[
E(dˆ|m, τ)
]
+ E
[
Var(dˆ|m, τ)
]
=
σ20
(n− 1)2 E
[
s2m (
∑n
i=1 miτi)
2
(σˆ21)
2
]
+
β201
n2
Var
[
(
∑n
i=1 miτi)
2
σˆ21
]
,
(4.30)
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but the distribution is complicated. We intend to investigate this further in the future with
the hope of modifying the current difference-in-coefficients tests, but the remainder of this
dissertation will focus on the conditional case.
As was mentioned previously, both the Freedman-Schatzkin test and the significance test
of d should be equivalent with respect to their test statistics and standard errors. In the
two-site case, dˆ = b03 − a03 = b13a12 is normally distributed with the following conditional
mean and variance:
E(dˆ|m, τ, s) = b13α12 (4.31)
Var(dˆ|m, τ, s) = b213Var(a12) =
b213σ
2
2
(1−R2(m))
∑N
i=1(mi − m¯)
, (4.32)
where σ22 = σ
2
0 −
σ201
σ21
= σ20(1− ρ2ym) and R2(m) is the multiple squared correlation from (4.8).
So, a t-test can be constructed with the following standard error: σˆ2d =
b213MSE2
(N − 1)s2m(1−R2(m))
,
where MSE2 is the estimate of the error variance in the conditional distribution of y.
The explicit power function of the d significance test is as follows:
power = P
(|t∗| > tn−5,1−α/2‖H1) = P (|tn−5,ψ| > tn−5,1−α/2) , (4.33)
where tn−5,ψ is a non-central t distribution with non-centrality parameter ψ =
∆√
σ2d
for the
alternative value ∆ = β03 − α03.
4.2.2 Power Analysis with 1 Mediator
Power analyses of each of the aforementioned 6 hypotheses were conducted using their explicit
power functions and the following assumptions. First, the overall design was assumed to have
two sites with two treatments at each site as well as equal sample sizes at each treatment-site
combination. Second, each of the mediated moderation equations were assumed to have the
same error variance of 1. As a consequence, (4.13) was simplified to
σˆ2 =
MSE
n
[
R2
1−R2
]
. (4.34)
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For each of the power analyses, partial correlation effect sizes were chosen to correspond to
small (.14), medium (.36), and large (.51). The sample sizes were chosen to be 50, 100, 200,
400, 500, and 1000. The overall type I error rate was chosen to be 0.05 for all hypothesis
tests. For the Freedman-Schatzkin test, the term
R2
1−R2 in the standard error is similar to
an f 2 effect size with 0.02, 0.15, and 0.35 values for small, medium, and large, respectively
[10]. The large effect of f 2, which corresponds to an R2 of 0.51, was chosen to give a lower
bound to power calculations. Similarly for the PSC test, R2(m) was chosen to be 0.51 for the
same reason. Since the true error variance for the d-test, σ22, involves the correlation between
the outcome and mediator variable (ρ2ym), this was set to 0.14
2 to exhibit a type of lower
bound for the power.
4.2.2.1 Results The results of the two difference-in-coefficients tests –
Freedman-Schatzkin and Olkin-Finn – were first examined (Table 1). Regarding the type
I error, both tests achieved alpha levels of approximately 0.05 regardless of sample size.
Nevertheless, it was the Freedman-Schatzkin test that attained greater power for a given
effect size and sample size, which mimicked the results obtained by MacKinnon et al. in the
basic mediation case [35].
Turning to the product-of-coefficients tests, we looked at the cases where both hy-
pothesized parameters were identical (α = β) as well as when they were not. In the first case,
when the product of standardized coefficients test was examined, both tests seemed to do
well in achieving an overall type I error of 0.05 although the combo test well underestimated
it at 0.001. In the case where one of the parameters varies, the issue of the inflated type I
error mentioned above appears (Table 2). For example as β increased for a given sample size,
the type I error rate of the combo test tended to 0.05 while the type I error of the product of
standardized coefficients test increased rapidly to 1. Despite the extremely low type I error
rate for the combo test, the size of the test is still 0.05. In order to clearly see this, consider
the first term of equation 4.21. Casella and Berger [9] showed that if one of probabilities is
sent to 1 (say, the right one), then the probability of the product is determined by the values
u1 and u3. So, in order to have an overall size of 0.05, u1 and u3 must be set to critical values
corresponding with 0.053 probability.
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Table 1: Type I error & power for MMM with 1 mediator
Sample Size
ES Method 50 100 200 400 500 1000
0
Freedman-Schatzkin 0.050 0.050 0.050 0.050 0.050 0.050
Olkin-Finn 0.050 0.050 0.050 0.050 0.050 0.050
d 0.050 0.050 0.050 0.050 0.050 0.050
0.14
Freedman-Schatzkin 0.373 0.647 0.914 0.997 >0.999 >0.999
Olkin-Finn 0.203 0.363 0.639 0.918 0.966 >0.999
d 0.133 0.224 0.400 0.679 0.774 0.970
0.36
Freedman-Schatzkin 0.988 >0.999 >0.999 >0.999 >0.999 >0.999
Olkin-Finn 0.857 0.993 >0.999 >0.999 >0.999 >0.999
d 0.572 0.869 0.993 >0.999 >0.999 >0.999
0.51
Freedman-Schatzkin >0.999 >0.999 >0.999 >0.999 >0.999 >0.999
Olkin-Finn 0.993 >0.999 >0.999 >0.999 >0.999 >0.999
d 0.859 0.992 >0.999 >0.999 >0.999 >0.999
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Figure 3: Power of Difference-in-Coefficients Tests
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As can be seen in Table 3, the variance stabilizing transformation (VST) method has
more accurate type I error as well as greater power than the combo method. Despite the fact
that as either α or β grow large the combo test tends to a 0.05 size test, there could be many
cases were neither one is large. As a consequence, the type I error will be underestimated
making the null hypothesis difficult to reject. On the other hand, the VST will always have
size 0.05 regardless of the value of the non-null parameter.
From the results of the power analysis, it is clear that both difference-in-coefficients tests
(Freedman-Schatzkin and Olkin-Finn) performed well in terms of high power and accurate
type I error. While the power of the product of standardized coefficients test was also large,
it suffered from an inflated type I error. The combo test, a result of the modification of the
product-of-coefficient’s hypotheses, resulted in high power with the caveat of the type I error
being underestimated.
Table 2: Type I error for MMM with 1 mediator and only one non-zero parameter
Sample Size
β Method 50 100 200 400 500 1000
0
Prod Stand Coef 0.050 0.050 0.050 0.050 0.050 0.050
Combo 0.001 0.001 0.001 0.001 0.001 0.001
0.14
Prod Stand Coef 0.107 0.162 0.264 0.428 0.491 0.687
Combo 0.003 0.005 0.010 0.020 0.025 0.041
0.36
Prod Stand Coef 0.377 0.571 0.764 0.895 0.905 0.907
Combo 0.016 0.031 0.046 0.050 0.050 0.050
0.51
Prod Stand Coef 0.572 0.765 0.895 0.907 0.907 0.963
Combo 0.030 0.046 0.050 0.050 0.050 0.050
MacKinnon et al. gives a thorough overview of the best methods for testing basic
mediation, while the goal of this dissertation is to extend those ideas to the multisite clinical
trial setting. The Freedman-Schatzkin test, the Olkin-Finn test, and MacKinnon’s product of
standardized coefficients test were chosen not only due to their uniqueness, but also because
they each had shown considerable power in the basic mediator setup. While the first two
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tests performed well in terms of both type I error and power, the last test suffered from the
same issue as in the basic mediator setup, inflated type I error. As a result, we rewrote the
hypothesis in terms of a combination of an intersection-union and a union-intersection test.
As the results showed, the level of the test was invariant to either of the parameters having
a true non-zero mean.
Table 3: Type I error & power for MMM with 1 mediator
Sample Size
ES Method 50 100 200 400 500 1000
0
Prod Stand Coef 0.050 0.050 0.050 0.050 0.050 0.050
VST 0.054 0.052 0.051 0.051 0.050 0.050
Combo 0.001 0.001 0.001 0.001 0.001 0.001
0.14
Prod Stand Coef 0.170 0.318 0.603 0.912 0.964 >0.999
VST 0.103 0.159 0.279 0.505 0.605 0.896
Combo 0.010 0.031 0.113 0.380 0.550 0.945
0.36
Prod Stand Coef 0.844 0.993 >0.999 >0.999 >0.999 >0.999
VST 0.432 0.736 0.963 >0.999 >0.999 >0.999
Combo 0.264 0.731 0.988 >0.999 >0.999 >0.999
0.51
Prod Stand Coef 0.993 >0.999 >0.999 >0.999 >0.999 >0.999
VST 0.741 0.964 >0.999 >0.999 >0.999 >0.999
Combo 0.712 0.988 >0.999 >0.999 >0.999 >0.999
We compared the power of the d significance test to that of the other two tests in the
difference-in-coefficients group with the results in Table 1. While the power of the d test is
clearly lower than the Freedman-Schatzkin and Olkin-Finn tests, an increase in ρ2ym to 0.51
2
increases the power by a factor 0.1511.
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4.2.3 Significance Testing with K Mediators
It is plausible that more than one variable could be responsible for the mediation of
treatment-by-site interaction. In this case, the mediated moderation setup as well as the
three significance tests can be extended. The three necessary equations – (4.2), (4.3), and
(4.4) – can be modified to reflect multiple mediators:
y = β00 + β01τ + β02s+ β03(τ ∗ s) + 0 (4.35)
m1 = β10 + β11τ + β12s+ β13(τ ∗ s) + 1 (4.36)
...
mK = βK0 + βK1τ + βK2s+ βK3(τ ∗ s) + K (4.37)
y = α00 + α01τ + α02s+ α03(τ ∗ s) + α12m1 + · · ·+ αK2mK + K+1. (4.38)
Based on the joint distribution of the outcome variable, y, and the mediators, we have
the following:
y
m1
...
mK
 ∼ N


β00 + β01τ + β02s+ β03(τ ∗ s)
β10 + β11τ + β12s+ β13(τ ∗ s)
...
βK0 + βK1τ + βK2s+ βK3(τ ∗ s)
 ,

σ20 σ01 . . . σ0K
σ10 σ
2
1 . . . σ1K
...
...
. . .
...
σK0 σK1 . . . σ
2
K


.
If we partition y from the mediator variables such that the variance-covariance matrix is
Σym =
 σ20 Σ0m
Σm0 Σmm
 ,
then the conditional distribution of y is
(y|m1, . . . ,mK , τ, s) ∼ N
(
µy + Σ0mΣ
−1
mm(m− µm), σ20 − Σ0mΣ−1mmΣm0
)
.
In the case of two mediators, it’s straightforward to show (see Appendix C) that the condi-
tional mean of y is
µy|m1,m2,τ,s = (β00 − α12β10 − α22β20) + (β01 − α12β11 − α22β21)τ
+(β02 − α12β12 − α22β22)s+ (β03τ − α12β13 − α22β23)(τ ∗ s)
+α12m1 + α22m2
= α00 + α01τ + α02s+ α03(τ ∗ s) + α12m1 + α22m2. (4.39)
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Figure 5: MMM Path Diagram: K Mediators
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4.2.3.1 Freedman & Schatzkin Test The three original tests are modified in the fol-
lowing ways: H0 : β03 − α03 = 0 with test statistic t∗ = b03 − a03√
σˆ2
∼ tn−4 where
σˆ2 = σˆ2b03 + σˆ
2
a03
− 2σˆb03σˆa03
√
1−R2
=
MSE0
n
+
MSEK+1
(1−R2)n − 2
√
MSE0
√
MSEK+1
n
, (4.40)
where R2 is the multiple correlation squared when τs is regressed on τ , s, and the mediators
m1,. . .,mK . Expressions for power are the same as in the single mediator case:
power = P
(|t∗| > tn−4,1−α/2‖H1) = P (|tn−4,ψ| > tn−4,1−α/2) (4.41)
where tn−4,ψ is a non-central t distribution with non-centrality parameter ψ =
∆√
σ2
for the
alternative value ∆ = β03 − α03.
4.2.3.2 Olkin & Finn Test H0 : ρys(τ) − ρys.1···K(τ) = 0 with the same test statistics
as before except that the functions fi now become:
fi(r) = rys − rys.1···K (4.42)
where the second term is the correlation between outcome and site at a particular treatment
level after accounting for the effects of the K mediators (denoted 1 · · ·K). Despite the fact
that higher order partial correlations can be decomposed into functions of zero-order partial
correlations, depending on K, fi(r) can be very complicated to compute. Raveh (1985)
showed that high-order partial correlations can be computed from the inverse correlation
matrix of all zero-order correlations involved [43]. For example with inverse correlation
P = R−1, the partial correlation of two variables i and j holding a set of variables ∆
constant is
rij.∆ =
−pij√
piipjj
. (4.43)
As was done in the single mediator case, the standard error of fi(r), aiΦia
′
i, is computed
where a is the vector of partial derivatives of fi(r) with respect to each pairwise correlation
of zero-order correlations. In the case of K mediators, the dimensions of a and Φ are
1-by-(K + 2) and (K + 2)-by-(K + 2).
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4.2.3.3 Product of Standardized Coefficients Test In the presence of K mediators,
the third test is now: H0 :
K∑
q=1
βq(τ)αq = 0 where βq(τ) = βq2 + βq3τ and αq = αq2
are independent, and test statistics L∗T =
K∑
q=1
(
bqT
σˆbqT
aq
σˆaq
)
and L∗C =
K∑
q=1
(
bqC
σˆbqC
aq
σˆaq
)
. The
main interest is on the pdf of L∗T and L
∗
C under the null hypothesis, which is the sum of
modified Bessel functions. Instead, each of the terms in the summation can be thought of
as normal scale mixtures. If we let Wq =
bq
σˆbq
aq
σˆaq
= µbqµaq (regardless of treatment), then
Wq = (Zbq + µbq)(Zaq + µaq) where Zbq and Zaq are independent standard normal variables.
After rearranging the terms, we get Wq = ZaqZbq + Xq where Xq ∼ N(µaqµbq , µ2aq + µ2bq).
This is equivalent in distribution to Wq = |Zaq |Zbq + Xs, where |Zaq |Zbq is a gaussian scale
mixture. The following is a theorem and corresponding proof.
Theorem 1. If Y = Z0Z1 and W = |Z0|Z1, where Z0 and Z1 are independent standard
normal variables, then Y and W are equal in distribution. In this case, W is distributed as
a scale mixture of a normal distribution with a chi-square mixing density.
Proof. Assume that W = |Z0|Z1. Because |Z0| is a special case of the folded normal dis-
tribution [13], |Z0| can be written as W = χ1Z1, where χ1 is a chi random variate with 1
degree of freedom. High order moments of W are given by the following:
E(W 2n) = E(χ2n1 )E(Z
2n
1 ) =
[
2nΓ(n+ 1/2)√
pi
] [
(2n)!
2nn!
]
=
[
(2n− 1)!!√pi√
pi2n
] [
(2n)!
n!
]
, (4.44)
where (2n − 1)!! denotes the double factorial of 2n − 1. This is equivalent to (2n)!
2nn!
, so the
above equation simplifies to:
E(W 2n) =
[
(2n)!
2nn!
]2
, (4.45)
which produces the exact same moments as the product of two standard normal variables.
By Carleman’s Condition (Chung 1974), if we can show that
∞∑
n=1
1
[E(W 2n)]1/(2n)
= +∞,
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then the sequence of moments produced by E(W 2n) is unique. So, using Stirling’s approxi-
mation we get
E(W 2n) ≈
[√
4pin
(
2n
e
)2n
2n
√
2pin
(
n
e
)n
]2
=
21+4n−2nn2n
e2n
≈
(
2n
e
)2n
, (4.46)
and subsequently,
∞∑
n=1
1
[E(W 2n)]1/(2n)
=
e
2
∞∑
n=1
1
n
= +∞.
Therefore, since the distribution of W is uniquely defined by a sequence of moments shared
by Y , then both Y and W must come from the same distribution. Hence Y and W are equal
in distribution. Alternatively, this can be proven by showing the equivalence of characteristic
functions.
In addition, the covariance between any two Gaussian variates, Zbq and Zbq′ , will be
assumed to be σqq′ . Conditioning on Zaq , Vq = Wq|Zaq ∼ N(µbqµaq , z2aq + µ2aq + µ2bq) with the
following covariance:
Cov(Vq, Vq′) = Cov(|zaq |Zbq +Xq, |zaq′ |Zbq′ +Xq′)
= |zaqzaq′ |Cov(Zbq , Zbq′ ) + |zaq |Cov(Zbq , Xq′) + |zaq′ |Cov(Zbq′ , Xq) + Cov(Xq, Xq′)
= |zaqzaq′ |σqq′ + |zaq |µaq′σqq′ + |zaq′ |µaqσqq′
= σqq′
(
|zaqzaq′ |+ |zaq |µaq′ + |zaq′ |µaq
)
(4.47)
Therefore, Li =
∑K
q=1 Vq is normally distributed with mean and variance:
E(Li) = E
(
K∑
q=1
Vq
)
=
K∑
q=1
µbqµaq (4.48)
Var(Li) = Var
(
K∑
q=1
Vq
)
=
K∑
q=1
Var(Vq) + 2
K∑
q 6=q′
Cov(Vq, Vq′)
=
K∑
q=1
(z2aq + µ
2
aq + µ
2
bq) + 2
K∑
q 6=q′
[
σqq′
(
|zaqzaq′ |+ |zaq |µaq′ + |zaq′ |µaq
)]
,
(4.49)
where |zaq | and |zaq′ | are folded normal random variables and z2aq is a chi squared random
variable.
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4.2.3.4 d Test Finally, the d significance test is extended to the K mediator case using
the distribution of y conditional on the mediator variables shown in Appendix C. H0 : d =
β03−α03 = 0 with estimate dˆ = b03− a03 =
∑K
q=1 bq3aq2. The conditional variance is derived
as follows:
Var(b03 − a03|m1, . . . ,mK , τ, s) =
K∑
q=1
b2q3Var(aq2) + 2
K∑
q 6=q′
bq3bq′3Cov(aq2, aq′2)
=
K∑
q=1
b2q3Var(aq2) + 2
K∑
q 6=q′
bq3bq′3
√
Var(aq2)
√
Var(aq′2)ρqq′
=
K∑
q=1
b2q3
MSEK+1
(N − 1)s2mq(1−R2(mq))
+2
K∑
q 6=q′
bq3bq′3
MSEK+1ρqq′
(N − 1)smqsmq′
√
(1−R2(mq))
√
(1−R2(mq′ ))
=
MSEK+1
N − 1
[
K∑
q=1
b2q3
1
s2mq(1−R2(mq))
+2
K∑
q 6=q′
bq3bq′3
ρqq′
smqsmq′
√
(1−R2(mq))
√
(1−R2(mq′ ))
 ,
(4.50)
where MSEK+1 is the estimate of the conditional variance of y, R
2
(mq)
is the multiple cor-
relation squared when the mediator mq is regressed on τ , s, τs, and the remaining K − 1
mediators, and ρqq′ is the correlation between aq2 and aq′2.
The power function for the d-test is
power = P
(|t∗| > tn−4−K),1−α/2‖H1) = P (|tn−4−K,ψ| > tn−4−K,1−α/2) , (4.51)
where tn−4−K,ψ is a non-central t distribution with non-centrality parameter ψ =
∆√
σ2
for
the alternative value ∆ = β03 − α03 and above conditional variance σˆ2.
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4.2.3.5 Limitations As with many significance tests, there are some limitations of ex-
tending the MMM tests to the K mediator case. With regard to the Olkin-Finn test, the
standard error of the test statistic involves a vector of partial derivatives of (4.42) with re-
spect to the outcome, the site, and each of the K mediator variables. It’s evident that even
with a modest number of mediators, (4.42) as a function of zero-order correlations can get
very complicated.
Another limitation involves the covariance parameters in the PSC and d tests. It’s
reasonable to assume that they are non-zero since the K mediators are correlated, but it
is not clear just how correlated they are. This will be investigated along with other future
work.
4.2.4 Illustration on TORDIA data
Each of the significance tests described so far all deal with the situation where the outcome
variable is continuous. In the TORDIA clinical trial, the outcome was dichotomous where
clinical response was defined as the combination of the Clinical Global Impressions (CGI)
score ≤ 2 and a change in the Children’s Depression Rating Scale-Revised (CDRS-R) of
≥ 50%. For the purposes of illustrating our six tests on this data, the change in the CDRS-
R was used as the outcome variable. In addition, since TORDIA involved six sites, the three
sites that were most similar in terms of their CBT-MED effect were combined into one. As
can be seen in Table 5, sites 1, 3, and 4 were combined into one site due to the similar direction
of their respective treatment effects. The three regression equations involved in mediated
Table 4: Treatment effect across sites for TORDIA data
Sites
TX 1 2 3 4 5 6 ALL
MED 0.503 0.446 0.465 0.511 0.342 0.312 0.435
CBT-MED 0.351 0.600 0.368 0.485 0.520 0.480 0.485
∆ 0.152 -0.154 0.097 0.026 -0.178 -0.168 -0.050
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moderation ((4.7), (4.8), and (4.9)) were each conducted with 20 variables measured at
baseline as potential mediators. First, there was overall site moderation of treatment effect
in (4.7) (b03 = −6.1478; p = 0.001) at the α = 0.10 significance level. Second, the conflict
behavior questionnaire score (CBQA) was the only variable in which there was a significant
treatment-by-site interaction in (4.8) (b13 = 0.6651; p = 0.053). Finally, overall moderation
was reduced after adjusting for CBQA (a03 = −5.6542; p = 0.002). Therefore, according to
Muller et al., the criteria for mediated moderation have been met.
We then applied the three difference-in-coefficients and three product-of-coefficients tests
to this data to see if the treatment-by-site interaction was significantly reduced. In the first
group, both the Freedman-Schatzkin and d significance tests concluded significant decreases
(pFS = 0.0108; pd = 0.0095), while the Olkin-Finn test did not (p = 0.4886). In the second
group, both MacKinnon’s product of standardized coefficients and the Combo test rejected
the null hypothesis (pPSC = 0.0249; pC = 0.0036), while the significance test based on the
variance stabilizing transformation did not (p = 0.9763).
One thing to note from this illustration is that while overall moderation was significantly
reduced after accounting for the CBQA mediator, it was not eliminated. So, CBQA explains
only part of the treatment-by-site interaction, and it could be the case that there are other
mediator variables involved in the explanation. Another issue in this illustration is that
while there were 20 variables checked for significant treatment-by-site interaction, there was
no adjustment for multiple comparisons. This is clearly a limitation to this procedure.
4.3 MMM IN THE J-SITE CASE
4.3.1 Significance Testing with 1 Mediator
The extension of the two-site mediated moderation model to the J-site case is straightfor-
ward. The three necessary equations are shown below:
yijl = µ0... + τ0i + s0j + γ0ij + 0ijl (4.52)
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mijl = µ1... + τ1i + s1j + γ1ij + 1ijl (4.53)
yijl = µ2... + τ2i + s2j + γ2ij + α1mijl + 2ijl (4.54)
where τ , s, γ, and m are the effect of treatment, site, their interaction, and the mediator
variable, respectively. As was the case in the two-site case, the equations above are based
on the joint distribution of y and m as well as the conditional distribution of y given m, τ ,
and s.  yijl
mijl
 ∼ N

 µ0... + τ0i + s0j + γ0ij + 0ijl
µ1... + τ1i + s1j + γ1ij + 1ijl
 ,
 σ20 σ01
σ01 σ
2
1
 ,
and
(yijl|mijl, τ, s) ∼ N
(
µ0... + τ0i + s0j + γ0ij +
σ01
σ21
(mijl − µ1... − τ1i − s1j − γ1ij) , σ20 −
σ201
σ21
)
,
and the conditional mean can be rewritten as
E(yijl|mijl, τ, s) =
(
µ0... − σ01
σ21
µ1...
)
+
(
τ0i − σ01
σ21
τ1i
)
+
(
s0j − σ01
σ21
s1j
)
+
(
γ0ij − σ01
σ21
γ1ij
)
+
σ01
σ21
mijl
= µ2... + τ2i + s2j + γ2ij + α1mijl, (4.55)
where i = 1, ..., I, j = 1, ...J , l = 1, ..., nij, and N =
∑2
i=1
∑J
j=1 nij. Equation (4.12) can
easily be extended to the GLM case such that
γ0ij − γ2ij = σ01
σ21
γ1ij = α1γ1ij. (4.56)
For (4.11), reparametrizing the marginal means of yijl and mijl so that µgi = µg... + τgi and
sgij = sgj + γgij for g = 0, 1, 2 gives the following equality:
s0ij − s2ij = σ01
σ21
s1ij = α1s1ij. (4.57)
The remainder of this work will revolve around the equality in (4.56) rather than (4.57)
because the primary goal is to investigate the change in site moderation rather than the
effect of site as a function of treatment.
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4.3.1.1 d Test The d significance test can be extended to the GLM framework as fol-
lows: H0 : dij = γ0ij − γ2ij = 0 for i = T,C with test statistics t∗ij =
dˆij
σˆdij
. Because there
are (I − 1)(J − 1) interaction parameters to estimate, one could imagine how monotonous
the union-intersection test could get when there are a modest number of sites. On the
other hand, the estimates of the interaction coefficients are correlated and have a unique
covariance structure. Consider a 2-treatment, J-site ANOVA model with the following pa-
rameter constraint:
2∑
i=1
τi =
J∑
j=1
sj =
2∑
i=1
γij =
J∑
j=1
γij = 0. Then conditional on m, τ and
s, dˆij = γˆ0ij − γˆ2ij = a1γˆ1ij is normally distributed with the following conditional mean and
variance:
E(dˆij|m, τ, s) = E(a1γˆ1ij) = γˆ1ijα1 (4.58)
Var(dˆij|m, τ, s) = Var(a1γˆ1ij) = γˆ21ij
σ22
(N − 1)s2m(1−R2(m))
. (4.59)
In addition, the conditional covariance between any two dˆij’s from differing sites, j and j
′, is
Cov(dˆij, dˆij′ |m, τ, s) = Cov (a1γˆ1ij, a1γˆ1ij′) = γˆ1ij γˆ1ij′ σ
2
2
(N − 1)s2m(1−R2(m))
. (4.60)
In matrix form, this is
dˆ11
dˆ12
...
dˆ1J−1
 ∼ N


µdˆ11
µdˆ12
...
µdˆ1J−1
 ,

σ2
dˆ11
σdˆ11dˆ12 . . . σdˆ11dˆ1J−1
σdˆ11dˆ12 σ
2
dˆ12
. . . σdˆ12dˆ1J−1
...
...
. . .
...
σdˆ11dˆ1J−1 σdˆ12dˆ1J−1 . . . σ
2
dˆ1J−1


,
where µdˆij , σ
2
dˆij
, and σdˆij dˆij′ represent the conditional means, variances, and covariances from
above. Under the assumption that µdˆ = 0, dˆ ∼ NJ−1(0,Σ).
A simplification of the distribution of dˆ is to use the equality in (4.56). So,
E(dˆ|m, τ, s) = E(γˆ1a1|m, τ, s)
= γˆ1α1 (4.61)
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and
Var(dˆ|m, τ, s) = Var(γˆ1a1|m, τ, s)
= γˆ1
σ22
(N − 1)s2m(1−R2(m))
γˆ1
′
=
σ22
(N − 1)s2m(1−R2(m))
γˆ1γˆ1
′, (4.62)
where R2(m) is the multiple correlation of the mediator variables regressed on τ , s, and γ.
The estimate of the above variance is
1
(N − 1)s2m(1−R2(m))
SSE2
N − 2J − 1 γˆ1γˆ1
′, which is a
scaled chi-squared random variable divided by degrees of freedom N −2J−1 and multiplied
by a vector of constants [24]. The null hypothesis can now be written as
H0 : d = 0 with test statistic
T 2 = dˆ′Σˆ−1dˆ
= (γˆ1a1)
′
(
MSE2
(N − 1)s2m(1−R2(m))
γˆ1γˆ1
′
)−1
(γˆ1a1)
= a21
(
MSE2
(N − 1)s2m(1−R2(m))
)−1
γˆ1
′(γˆ1γˆ1
′)−γˆ1
= a21
(
MSE2
(N − 1)s2m(1−R2(m))
)−1
, (4.63)
where ()− denotes the generalized inverse of the singular matrix γˆ1γˆ1
′. It is easy to show
that γˆ1
′(γˆ1γˆ1
′)−γˆ1 reduces to one (see Appendix E). The test statistic is distributed as
F1,N−2J−1. The critical values are chosen such that
α = PH0
(
T 2 > F1,N−2J−1,1−α
)
. (4.64)
Under the alternative hypothesis, T 2 is distributed as a non-central F random variable with
non-centrality parameter, ψ =
∆2
σ2
where ∆ = α1 and σ
2 = Var(a1). Therefore, the power is
calculated as follows:
power = P (F1,N−2J−1,ψ > F1,N−2J−1,1−α) . (4.65)
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4.3.1.2 Product of Standardized Coefficients Test In the GLM framework, MacK-
innon’s PSC test can be extended to the multivariate case, but it is difficult because a
multivariate Bessel distribution has not been studied yet. Since there are J − 1 estimates
of the treatment-by-site interactions, there will be just as many product-of-coefficients es-
timates. Marginally, each of the estimates is the product of normal random variables each
with unit variance:

a1
σa
γˆ111
σγˆ
a1
σa
γˆ112
σγˆ
...
a1
σa
γˆ11J−1
σγˆ

∼


α1
σα
γ111
σγ
α1
σα
γ112
σγ
...
α1
σα
γ11J−1
σγ

,
[
Σαγ
]

,
where Σαγ is the variance-covariance matrix with
Var
(
a1
σa
γˆ11j
σγˆ
)
=
(
γ11j
σγ
)2
+
(
α1
σα
)2
+ 1 (4.66)
on the diagonals and
Cov
(
a1
σa
γˆ11j
σγˆ
,
a1
σa
γˆ11j′
σγˆ
)
= (MSE1)
(
σˆ01
σˆ21
)2 [
1
4J2
2∑
i=1
J∑
j=1
(
1
nij
)
− 1
4J
2∑
i=1
(
1
nij
+
1
nij′
)]
+
(
γ11j
σγ
γ11j′
σγ
)(
1−
(
α1
σα
)2)
(4.67)
on the off-diagonals. While the variance was derived by Craig [12], the derivation of covari-
ance of any two estimates can be shown in the following example.
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Assume that X1, Xj, and Xj′ are all random variables with unit variance and respective
means µ1, µj, and µj′ . Also, X1 ⊥ Xj, X1 ⊥ Xj′ , and Cov(Xj, Xj′) = σjj′ . Then
Cov(X1Xj, X1Xj′) = E(X
2
1XjXj′)− E(X1Xj)E(X1Xj′)
= E
[
E(X21XjXj′|X1)
]− µ21µjµj′
= E
[
X21 E(XjXj′)
]− µ21µjµj′
= E
[
X21 (σjj′ + µjµj′)
]− µ21µjµj′
= (σjj′ + µjµj′)− µ21µjµj′ = σjj′ + µjµj′(1− µ21).
(4.68)
The difficulty arises in the multivariate distribution of the above vector of estimates. To
simplify this problem, let us go back to the two-site case. In this case,
a1
σa
γˆ111
σγˆ
is distributed
as the product of two normal random variables each with unit variance. Under the null
hypothesis assumed by MacKinnon (α1 = γ = 0), this is distributed as the product of two
standard normal variables, denoted by Y = Z0Z1, which has the density function pi
−1K0(|Y |).
The following theorem shows that a vector of correlated Bessel functions, Y, can instead be
denoted as a multivariate normal scale mixture.
Theorem 2. Let Y = Z0Z and W = |Z0|Z, where Z0 is a standard normal random variable
independent of Z, which is a p-dimensional vector coming from a multivariate normal distri-
bution with zero mean vector and covariance matrix Σ. Then Yis equivalent in distribution
to W. In this case, W is distributed as a scale mixture of a multivariate normal distribution
with a chi-square mixing density.
Proof. The simplest way to prove this is by showing the equivalence of the characteristic
functions of Y and W. So,
φY(t) = E (exp{it′Z0Z}) = E [E (exp{it′Z0Z}|Z0)]
= E
(
exp
{−Z20t′Σt
2
})
= (1 + t′Σt)−1/2
= φW(t). (4.69)
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Theorem 3. Let Y = (Z0 + µ0)(Z + µ) and W = |Z0|Z + X where X ∼ MVN(µ0µ, µ20Σ +
µµ′), and Z0 and Z are independent of each other and defined in the previous theorem. Then
Y and W are equal in distribution.
Proof. We can rewrite Y so that it is the sum of independent components:
Y = Z0Z + µ0Z + µZ0 + µ0µ. (4.70)
If we denote the sum of the last three terms as X, it’s easy to show that this is the sum of
two multivariate normal random variables and a vector of scalars. So,
(µ0Z) ∼ MVN(0, µ20Σ)
and
(µZ0) ∼ MVN(0,µµ′)
and are independent of each other. Therefore, X ∼ MVN(µ0µ, µ20Σ + µµ′). The character-
istic function is as follows:
φY(t) = φZ0Z(t)φX(t) = φ|Z0|Z(t)φX(t), (4.71)
where the second equality comes from Theorem 2.
φY(t) = φ|Z0|Z(t)φX(t)
= (1 + t′Σt)−1/2exp
{
it′µ0µ− 1
2
t′
(
µ20Σ + µµ
′) t}
= φW(t). (4.72)
Since both Y and W have the same characteristic functions, they’re equal in distribution.
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Now that an appropriate multivariate distribution has been identified, we can now con-
tinue with the details of the PSC significance test. H0 : α1γ1 = 0 where γ is a J − 1
dimensional vector of the interaction parameters. Following MacKinnon et al., the test
statistic is W =
a1
σa
γˆ
σγˆ
and is distributed under the alternative hypothesis as a scale mix-
ture of multivariate normal random variables with the following conditional and marginal
densities:
(W|z0) ∼ MVN
(
α1
σα
γ
σγ
,
(
z20 +
(
α1
σα
)2)
Σγ +
γ
σγ
γ
σγ
′
)
where
z20 ∼ χ21
and Σγ is the variance-covariance matrix of the standardized interaction estimates (see Ap-
pendix D). A Hotelling’s T 2 test can be conducted with test statistic
T 2 = W′(z20Σˆγ)
−1W. Under the null hypothesis, (T 2|z20) ∼ (N−2J)(J−1)N−3J+2 FJ−1,N−3J+2, so the
critical values are chosen such that
α = PH0
(
T 2 >
(N − 2J)(J − 1)
N − 3J + 2 FJ−1,N−3J+2,1−α
)
= PH0
(
N − 3J + 2
(N − 2J)(J − 1)T
2 > FJ−1,N−3J+2,1−α
)
. (4.73)
Under the alternative hypothesis, N−3J+2
(N−2J)(J−1)T
2 is distributed as a non-central F random
variable with non-centrality parameter,
ψ =
(
α1
σα
γ
σγ
)′((
z20 +
(
α1
σα
)2)
Σγ +
γ
σγ
γ
σγ
′
)−1 (
α1
σα
γ
σγ
)
[18]. Therefore, the power is calculated
as follows:
power = P (FJ−1,N−3J+2,ψ > FJ−1,N−3J+2,1−α) . (4.74)
As in the two-site case, the null hypothesis described by MacKinnon can only arise when
both parameters, α1 and γ, are zero. The only requirement for the general null hypothesis
is that either of the two parameters is zero, so the inflated type I error issues described in
the two-site case apply here as well.
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4.3.2 Power Analysis with 1 Mediator
Power analyses of each of the above significance tests were conducted using their explicit
power functions and the following assumptions. First, the overall design was assumed to
have two treatments at each of J sites as well as as equal sample sizes at each treatment-
site combination. Second, σ20 and σ
2
1 were assumed to be 1. Finally, each of the γˆ1ij, the
interactive effects of treatment and site on the mediator variable, were identically chosen to
be 1. For each of the power analyses, effect sizes were chosen to correspond to small (.20),
medium (.50), and large (.80) according to Cohen [10]. The sample sizes were chosen to be
100, 200, 400, 500, and 1000. In addition, the number of sites were chosen to be 5, 10, and
20. The overall type I error rate was chosen to be 0.05 for all hypothesis tests.
For the PSC test, the non-centrality parameter involves σα =
1√
1−R2(m)
, where R2(m)
is the multiple correlation of the mediator variables regressed on τ , s, and γ. Just as in the
two-site, two-treatment case, R2(m) was chosen to be 0.51. Also, the test statistic T
2 contains
a chi-squared random variable, z20 . Therefore, the first, second, and third quartiles of χ
2
1
were chosen for values of z20 .
4.3.2.1 Results The results of the d and PSC tests are displayed in the following three
tables. When the values of z20 were varied, the differences in the resulting power were
negligible. Therefore, only the first quartile of χ21 was used. Unlike in the two-site case, the
PSC test is much more powerful than the d test regardless of the number of sites. Also, the
power of the d test did not decrease with the number of sites as rapidly as the PSC test did.
As in the two-site case, the issue of inflated type I error in the PSC test may occur. The
degree to which this effects the significance test will be investigated in future work. Similar to
the variance stabilizing transformation used previously, a logarithmic transformation could
be used on the test statistic, W, as a remedy for the inflated type I error.
4.3.3 Illustration on TORDIA data
As in the two-site case, each of the significance tests was conducted on the TORDIA clinical
trial dataset with the outcome being the change in the CDRS-R variable. Since this is a
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Table 5: Type I error & power for MMM with 1 mediator and j = 5 sites
Sample Size
ES Method 100 200 400 500 1000
0
d 0.050 0.050 0.050 0.050 0.050
Prod Stand Coef 0.050 0.050 0.050 0.050 0.050
0.20
d 0.395 0.675 0.929 0.970 >0.999
Prod Stand Coef 0.898 0.998 >0.999 >0.999 >0.999
0.50
d 0.989 0.999 >0.999 >0.999 >0.999
Prod Stand Coef >0.999 >0.999 >0.999 >0.999 >0.999
0.80
d >0.999 >0.999 >0.999 >0.999 >0.999
Prod Stand Coef >0.999 >0.999 >0.999 >0.999 >0.999
Table 6: Type I error & power for MMM with 1 mediator and j = 10 sites
Sample Size
ES Method 100 200 400 500 1000
0
d 0.050 0.050 0.050 0.050 0.050
Prod Stand Coef 0.050 0.050 0.050 0.050 0.050
0.20
d 0.394 0.675 0.929 0.970 >0.999
Prod Stand Coef 0.785 0.992 >0.999 >0.999 >0.999
0.50
d 0.988 >0.999 >0.999 >0.999 >0.999
Prod Stand Coef 0.998 >0.999 >0.999 >0.999 >0.999
0.80
d >0.999 >0.999 >0.999 >0.999 >0.999
Prod Stand Coef >0.999 >0.999 >0.999 >0.999 >0.999
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Table 7: Type I error & power for MMM with 1 mediator and j = 20 sites
Sample Size
ES Method 100 200 400 500 1000
0
d 0.050 0.050 0.050 0.050 0.050
Prod Stand Coef 0.050 0.050 0.050 0.050 0.050
0.20
d 0.391 0.674 0.929 0.970 >0.999
Prod Stand Coef 0.526 0.956 >0.999 >0.999 >0.999
0.50
d 0.988 >0.999 >0.999 >0.999 >0.999
Prod Stand Coef 0.958 >0.999 >0.999 >0.999 >0.999
0.80
d >0.999 >0.999 >0.999 >0.999 >0.999
Prod Stand Coef 0.999 >0.999 >0.999 >0.999 >0.999
multisite example, the original six sites and their respective data were preserved.
The three models in the multisite mediated moderation case ((4.52), (4.53), and (4.54))
were conducted with 20 variables measured at baseline as potential mediators. There was
overall site moderation of treatment effect in (4.52) (p = 0.025) at the α = 0.05 significance
level. There were two variables in which significant treatment-by-site interaction persisted:
1) the CBQA variable mentioned in the previous section (p = 0.044), and 2) the TOTALD
variable (p = 0.004), which is a measure of the Drug Use Screening Inventory (DUSI).
After adjusting for the CBQA score, the magnitude of site moderation was reduced
(p = 0.066), which is a criterion for mediated moderation. Moreover, the interaction was non-
significant after the adjustment. Both tests were applied to the data to see if the reductions in
magnitudes were significant. Since the PSC test involves a χ21 random variable, the expected
value of 1 was chosen. The d test concluded that subject’s CBQA score significantly explained
the differing effect of CBT-MED therapy across the six sites (p = 0.0153). The Product of
Standardized Coefficients test concluded that the magnitude of interaction was significantly
reduced (p < 0.001). This agrees with the conclusions of the paper by Spirito et al.
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As was the case with the CBQA variable, the magnitude of site moderation due to the
adjustment for the TOTALD variable was reduced (p = 0.041). Both of the aforementioned
tests were applied to the data and only the PSC test concluded a significant reduction
(pd = 0.193; pPSC < 0.001). In other words, there were conflicting results as to whether the
TOTALD score alone explained the differing effects of CBT-MED therapy across sites.
56
5.0 MMM IN GENERALIZED LINEAR MODELS
5.1 LOGISTIC REGRESSION
There has not been much in the literature with regards to mediation in logistic regression
models. Huang et al. used structural equation models (SEM) to give a causal interpretation
of the meditational effect in the logistic model setting [22]. More recently, MacKinnon et al.
presented a comprehensive overview of the difference-in-coefficients, product-of-coefficients,
and the proportion mediated effect methods in the case of a binary independent variable
[34]. As in the regression and ANOVA cases, no one to this author’s knowledge has extended
logistic mediation models to the multisite clinical trial setting.
In the logistic regression case, the three necessary equations described in the previous
chapter can be extended without difficulty. Instead of being written in regression form, they
are presented in terms of the expected values of the outcome y and mediator m, respectively.
logit[E(yijl)] = µ0... + τ0i + s0j + γ0ij (5.1)
E(mijl) = µ1... + τ1i + s1j + γ1ij (5.2)
logit[E(yijl)] = µ2... + τ2i + s2j + γ2ij + α1mijl (5.3)
where τ , s, γ, and m are the effect of treatment, site, their interaction, and the mediator
variable, respectively. The subscript ijl represents the l-th person in the j-th site taking the
i-th treatment. Unlike in the regression and ANOVA cases, the necessary equations in the
logistic case cannot be derived from the bivariate normal distribution. Instead, the equations
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are derived from the marginal distribution of m and the conditional distribution of y:
(mijl|τ, s) ∼ N
(
µm, σ
2
1
)
where µm is (5.2) and
(yijl|m, τ, s) ∼ Bernoulli(pij)
where pij =
1
1 + e−µ2...−τ2i−s2j−γ2ij−α1mijl
. Therefore the marginal distribution of y is
f(yijl|τ, s) =
∫ ∞
−∞
f(y|mijl, τ, s)f(mijl|τ, s)dm
=
∫ ∞
−∞
p
yijl
ij (1− pij)1−yijl
1√
2piσ21
exp
(−(mijl − µm)2
2σ21
)
dm,
(5.4)
and the marginal expectation of y is
E(yijl|τ, s) = E [E(yijl|mijl, τ, s)] = E(pij|τ, s)
=
∫ ∞
−∞
1
1 + e−w
1√
2piσ2w
exp
(−(w − µw)2
2σ2w
)
dw, (5.5)
where w = µ2...+τ2i+s2j+γ2ij+α1mijl is a normal random variable with mean and variance:
µw = µ2... + τ2i + s2j + γ2ij + α1µ1... + α1τ1i + α1s1j + α1γ1ij
= (µ2... + α1µ1...) + (τ2i + α1τ1i) + (s2j + α1s1j) + (γ2ij + α1γ1ij)
= µ0... + τ0i + s0j + γ0ij
σ2w = α
2
1σ
2
1.
Frederic & Lad [15] showed that p comes from a logitnormal distribution with density
f(pij|τ, s) = 1√
2piσ2wpij(1− pij)
exp
(
− (logit(pij)− µw)2
2σ2w
)
, (5.6)
where the logit function is defined as logit(x) = log
(
x
1−x
)
. With regard to the moments of
a logitnormal random variable, unless µw is 0, the expected value and variance cannot be
obtained in closed form [15].
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In order to obtain (5.1), the logit function of (5.5) needs to be linear with respect to
the marginal expectation of the mediator variable, µm. To investigate the above assertion,
we conducted a simulation study that computed the integral in (5.5), using Gauss-Legendre
quadrature with 100 knots [1], for varying values of µw ∈ [−10, 10] and σw ∈ [1, 3, 5]. For
each combination of µw and σw parameter values, E(p) and logit[E(p)] were computed. Below
are separate plots of the expectation and logit versus µw.
It’s evident from Figure 6 that E(p), and hence the marginal expectation of y, is sigmoidal
regardless of the value of σw. Also, all three curves intersect at µw = 0 which represents
the only closed form for E(p), which is 0.5. Taking the logit of each of the curves helps to
linearize them with the most pronounced effect when σw = 1.
This simulation study shows that the logit of the marginal expectation of y is approxi-
mately linear with respect to the marginal expectation of m. In other words:
logit[E(yijk|τ, s)] ≈ µ0... + τ0i + s0j + γ0ij.
Similar to the MMM case with a continuous outcome, there is a useful equality that arises
although it is now an approximation:
γ0 − γ2 ≈ γ2 + α1γ1 − γ2 = α1γ1. (5.7)
An estimate of d = γ0 − γ2 is dˆ = γˆ0 − γˆ2 ≈ a1γˆ1 with the following mean and variance:
E(dˆ|τ, s,m) = γˆ1α1 (5.8)
Var(dˆ|τ, s,m) = γˆ1Var(a1|τ, s,m)γˆ ′1. (5.9)
To get the conditional variance of the estimate, a1, one has to go back to parameter estimation
in generalized linear models. A standard result is:
θˆ ∼ AN (θ, I−1(θ)) ,
where θˆ is the vector of parameter estimates and I(θ) is the respective Fisher Information
[36]. In the logistic regression case,
I(θ) = −E
(
∂2logL
∂θ2
)
= X′WX,
59
−10 −8 −6 −4 −2 0 2 4 6 8 10
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
µw
E(
p)
 
 
!w=1
!w=3
!w=5
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where W is a diagonal matrix with pij(1− pij) as the entries. Since
θˆ
′
=
[
µˆ... τˆ1 sˆ1 . . . sˆJ−1 γˆ11 . . . γˆ1J−1
]
, then the large sample multivariate distri-
bution of the parameter estimates is asymptotically
θˆ ∼ N
(
θ, (X′WX)−1
)
.
5.1.1 Significance Testing with 1 Mediator
We now extend the d-test and PSC test to the logistic regression case. The first test is as
follows:
5.1.1.1 d Test H0 : d = γ0 − γ2 = 0 with test statistic
T 2 = (γˆ1a1)
′
[
γˆ1(X
′WX)−1a γˆ1
′
]−1
(γˆ1a1)
= a21
[
(X′WX)−1a
]−1 [
γˆ1
′(γˆ1γˆ1
′)−γˆ1
]
=
a21
(X′WX)−1a
, (5.10)
where subscript a denotes the matrix entry corresponding to the parameter estimate of the
mediator. Under the null hypothesis, T 2 is distributed as a χ21, so the critical values are
chosen such that
α = PH0
(
T 2 > χ21,1−α
)
. (5.11)
This is also known as a Wald test [36].
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5.1.1.2 Product of Standardized Coefficients Test The PSC significance test in
the logistic case is similar to that of the ANOVA case: H0 : α1γ1 = 0, where γ is a J − 1
dimensional vector of the interaction parameters. The product α1γ1 is estimated by a1γˆ1,
where
a1 ∼ N
(
α1, (X
′WX)−1a
)
and
γˆ1 ∼MVN
(
γ1, (X
′WX)−1γ
)
.
Following MacKinnon et al, the test statistic is W =
a1
σa
γˆ
σγˆ
, which is distributed under the
alternative hypothesis as a scale mixture of multivariate normal random variables with the
following conditional and marginal densities:
(W|z0) ∼MVN
(
α1
σα
γ
σγ
,
(
z20 +
(
α1
σα
)2)
Σγ +
γ
σγ
γ
σγ
′
)
where
z20 ∼ χ21
and Σγ is the variance-covariance matrix of the standardized interaction estimates with a
diagonal entry of ones and off-diagonal entries:
(Σγ)ij =
(X ′WX)−1ij√
(X ′WX)−1ii
√
(X ′WX)−1jj
.
A Wald test can be conducted with test statistic T 2 = W′(z20Σˆγ)
−1W, and under the null
hypothesis (T 2|z20) is distributed as χ2J−1. Critical values are chosen such that
α = PH0
(
T 2 > χ2J−1,1−α
)
. (5.12)
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5.1.2 Simulation Study with 1 Mediator
To estimate power, a simulation study was conducted for each of the above significance
tests. First, the mediator and outcome variables were drawn according to the following
distributions:
(mijl|τ, s) ∼ N
(
µ1... + τ1i + s1j + γ1ij, σ
2
1
)
and
(yijl|m, τ, s) ∼ Bernoulli(pij),
where pij = (1 + exp[−(µ2... + τ2i + s2j + γ2ij + α1mijl)])−1.
We used the TORDIA clinical trial as a basis for selecting the parameter values in our
simulation study. The grand means and treatment effects were µ1... = 1.48, µ2... = 1.01,
τ11 = 0.57, and τ21 = −1.24, respectively. The values for the site parameters in both
distributions were s1j = {0.38,−0.10,−0.04, 0.04} and s2j = {−0.79,−1.06,−0.30,−1.66}.
The interaction values for the distribution of the response variable were
γ21j = {2.47, 1.62, 1.09, 3.07, 2.95}.
Regarding the effect size, we used the approximation from (5.7). The coefficient of
the mediator α1 was set to equal
√
es, the square root of the effect size. In addition, the
interaction parameter values, γ11, γ12, . . . , γ1,J−1, were generated from the same distribution
above with the exception that the mean was
√
es. Effect size values of zero, small (0.20),
medium (0.50), and large (0.80) were chosen according to Cohen [10]. The sample sizes were
chosen to be 100, 200, 400, 500, and 1000. In addition, the number of sites were chosen to
be 2 and 5. In the former case, only the first value was chosen from s1j, s2j, and γ21j, while
all the values were chosen in the latter case. Also, the test statistic for the PSC test, T 2,
contains a chi-squared random variable, z20 . Therefore, the first, and third quartiles as well
as the expected value of χ21 were chosen for values of z
2
0 .
For each of the effect size/sample size/site number combinations, the three necessary
equations ((5.1), (5.2), (5.3)) were fit and the two significance tests were conducted 10,000
times. The number of times the null hypothesis was rejected gave an estimate of the type I
error and power.
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5.1.2.1 Results The results of the simulation study for the d test are presented in Tables
8 & 9. With only 2 sites, both the d and PSC tests seem fairly close with regards to power,
although it appears the type I error of the PSC is consistently overestimating the true value of
0.05. This phenomenon is similar to the what was happening in the regression and ANOVA
cases, although the reason behind it is not the same. One of the things that MacKinnon et
al showed was that the useful equality (in the logistic MMM case: γ0 − γ2 = α1γ1) does
not hold at times [34]. When the number of sites increases to 5, this issue is even more
pronounced – namely in the n = 100 and n = 200 cases.
Table 8: Type I error & power for logistic MMM with 1 mediator and j = 2 sites
Sample Size
ES Method 100 200 400 500 1000
0
d 0.052 0.046 0.048 0.046 0.048
PSC 0.073 0.065 0.070 0.069 0.076
0.20
d 0.481 0.680 0.928 0.970 >0.999
PSC 0.465 0.692 0.939 0.968 0.998
0.50
d 0.768 0.930 0.997 0.999 >0.999
PSC 0.757 0.963 0.999 0.999 >0.999
0.80
d 0.872 0.979 >0.999 >0.999 >0.999
PSC 0.905 0.998 >0.999 >0.999 >0.999
To investigate this, I conducted a simulation study with the same setup as the preceding
one, but only with j = 2 sites. For each of the 10,000 iterations, I computed the estimates
γˆ0 − γˆ2 and a1γˆ1 as well as their squared difference from the true value. The mean, stan-
dard deviation, and mean square error were then calculated for each sample size/effect size
combination.
As can be seen in Table 10, the product of coefficients does a better job than the difference
in coefficients in estimating the true effect. The difference is stark with smaller sample sizes.
The fact that γˆ0− γˆ2 severely overestimates the truth (especially in the case of a large effect
size and small sample size) can lead to an exaggerated estimate of power. In the j = 5 case,
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Table 9: Type I error & power for logistic MMM with 1 mediator and j = 5 sites
Sample Size
ES Method 100 200 400 500 1000
0
d 0.252 0.068 0.048 0.050 0.052
PSC 0.337 0.157 0.128 0.155 0.131
0.20
d 0.874 0.818 0.950 0.979 >0.999
PSC 0.917 0.867 0.969 0.990 >0.999
0.50
d 0.981 0.983 0.999 >0.999 >0.999
PSC 0.987 0.989 >0.999 >0.999 >0.999
0.80
d 0.993 0.999 >0.999 >0.999 >0.999
PSC 0.993 0.998 >0.999 >0.999 >0.999
there is an added issue of cell size. When n = 100, there are only 10 samples in each of
the 10 treatment-by-site cells. As a result, complete separation can occur when all of the
responses in a particular cell are identical. Since the PSC test involves a χ2 random variable,
type I error and power were re-estimated with the lower and upper quartiles of χ21 and χ
2
4,
respectively. As can be seen in tables 11 & 12, as the χ2 value decreases, so do the type I
error and power.
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Table 10: Comparison of estimators in logistic MMM with 1 mediator and j = 2 sites
Sample Size
ES Method 100 200 400 500 1000
0
γˆ0 − γˆ2
Mean -0.026 -0.013 -0.007 -0.005 -0.003
SD 0.129 0.048 0.025 0.020 0.010
MSE 0.017 0.003 0.001 <0.001 <0.001
a1γˆ1
Mean >-0.001 >-0.001 >-0.001 >-0.001 >-0.001
SD 0.097 0.045 0.023 0.018 0.010
MSE 0.010 0.002 0.001 <0.001 <0.001
0.20
γˆ0 − γˆ2
Mean 0.336 0.151 0.123 0.117 0.102
SD 0.728 0.340 0.110 0.088 0.059
MSE 0.558 0.117 0.018 0.014 0.010
a1γˆ1
Mean 0.181 0.194 0.201 0.199 0.181
SD 0.255 0.166 0.113 0.100 0.068
MSE 0.065 0.028 0.013 0.010 0.005
0.50
γˆ0 − γˆ2
Mean 1.178 0.800 0.470 0.360 0.340
SD 1.468 1.040 0.529 0.352 0.116
MSE 2.772 1.178 0.282 0.136 0.035
a1γˆ1
Mean 0.430 0.517 0.531 0.476 0.492
SD 0.408 0.279 0.191 0.162 0.116
MSE 0.168 0.079 0.037 0.026 0.013
0.80
γˆ0 − γˆ2
Mean 2.421 1.997 1.325 0.891 0.646
SD 2.247 1.682 1.317 0.994 0.438
MSE 8.001 4.085 1.916 1.002 0.215
a1γˆ1
Mean 0.796 0.930 0.922 0.788 0.807
SD 0.576 0.393 0.266 0.222 0.157
MSE 0.341 0.157 0.071 0.050 0.025
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Table 11: Type I error & power for logistic PSC test with varying χ2 and j = 2 sites
Sample Size
ES χ21,α 100 200 400 500 1000
0
α = 0.25 0.355 0.338 0.353 0.356 0.373
α = 0.75 0.052 0.046 0.049 0.050 0.056
0.20
α = 0.25 0.764 0.899 0.987 0.994 >0.999
α = 0.75 0.419 0.645 0.928 0.960 0.998
0.50
α = 0.25 0.919 0.992 >0.999 >0.999 >0.999
α = 0.75 0.720 0.950 0.999 0.999 >0.999
0.80
α = 0.25 0.978 >0.999 >0.999 >0.999 >0.999
α = 0.75 0.885 0.997 >0.999 >0.999 >0.999
Table 12: Type I error & power for logistic PSC test with varying χ2 and j = 5 sites
Sample Size
ES χ24,α 100 200 400 500 1000
0
α = 0.25 0.691 0.593 0.578 0.603 0.582
α = 0.75 0.302 0.117 0.090 0.108 0.089
0.20
α = 0.25 0.985 0.985 0.999 >0.999 >0.999
α = 0.75 0.900 0.829 0.952 0.982 >0.999
0.50
α = 0.25 0.999 0.999 >0.999 >0.999 >0.999
α = 0.75 0.979 0.983 >0.999 >0.999 >0.999
0.80
α = 0.25 0.999 >0.999 >0.999 >0.999 >0.999
α = 0.75 0.991 0.997 >0.999 >0.999 >0.999
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5.1.3 Significance Testing with K Mediators
The necessary equations from (5.1), (5.2), and (5.3) can be extended to the K mediator case
in the following way:
logit[E(yijl)] = µ0... + τ0i + s0j + γ0ij (5.13)
E(m1ijl) = µ1... + τ1i + s1j + γ1ij (5.14)
...
E(mKijl) = µK... + τKi + sKj + γKij (5.15)
logit[E(yijl)] = µK+1... + τK+1,i + sK+1,j + γK+1,ij + α1m1ijl + · · ·+ αK+1mK+1,ijl.
(5.16)
In terms of the multivariate distribution of the mediators, m1, · · · ,mK , and the conditional
distribution of the outcome variable, we have

m1
...
mk
 ∼ N


µ1... + τ1i + s1j + γ1ij
...
µK... + τKi + sKj + γKij
 ,

σ21 σ12 . . . σ1K
σ21 σ
2
2 . . . σ2K
...
...
. . .
...
σK1 σK2 . . . σ
2
K


,
and
(yijl|m1, · · · ,mK , τ, s) ∼ Bernoulli(pij),
where pij =
1
1 + e−(µK+1...+τK+1,i+sK+1,j+γK+1,ij+α1m1ijl+···+αK+1mK+1,ijl)
. As in the single medi-
ator case, the density of the marginal distribution of y is
f(y|τ, s) =
∫ ∞
−∞
· · ·
∫ ∞
−∞
f(y|m, τ, s)f(m|τ, s)dm
=
∫ ∞
−∞
· · ·
∫ ∞
−∞
py(1− p)1−y(2pi)−K/2|Σm|−1/2exp
(−1
2
(m− µm)′Σ−1m (m− µm)
)
dm.
(5.17)
From above, we can obtain the marginal expectation of the outcome:
E(y|τ, s) = E [E(y|m, τ, s)] = E(p|τ, s)
=
∫ ∞
−∞
1
1 + e−w
1√
2piσ2w
exp
(−(w − µw)2
2σ2w
)
dw, (5.18)
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where w = µK+1... + τK+1,i + sK+1,j + γK+1,ij +
∑K
q=1 αqmqijl is a normal random variable
with mean and variance:
µw = µK+1... + τK+1,i + sK+1,j + γK+1,ij +
K∑
q=1
αqµq... +
K∑
q=1
αqτqi +
K∑
q=1
αqsqj +
K∑
q=1
αqγqij
= (µK+1... +
K∑
q=1
αqµq...) + (τK+1,i +
K∑
q=1
αqτqi) + (sK+1,j +
K∑
q=1
αqsqj) + (γK+1,ij +
K∑
q=1
αqγqij)
= µ0... + τ0i + s0j + γ0ij
σ2w =
K∑
q=1
α2qσ
2
q + 2
K∑
q 6=q′
αqαq′σqq′ .
If we adhere to the linearity assumption between the marginal expectation of y and the
marginal expectation of m that was shown in the single mediator case, the following approx-
imation arises:
γ0 − γK+1 ≈
K∑
q=1
αqγq. (5.19)
An estimate of d = γ0 − γK+1 is dˆ = γˆ0 − γˆK+1 ≈
∑K
q=1 aqγˆq with the following mean and
variance:
E(dˆ|τ, s,m) =
K∑
q=1
γˆqαq (5.20)
Var(dˆ|τ, s,m) =
K∑
q=1
γˆq(X
′WX)aq γˆ
′
q + 2
K∑
q 6=q′
γˆq(X
′WX)aq ,aq′ γˆ
′
q′ . (5.21)
5.1.3.1 d Test The null hypothesis is H0 : d = γ0 − γK+1 = 0 with test statistic
T 2 =
(
K∑
q=1
aqγˆq
)′ [ K∑
q=1
γˆq(X
′WX)aq γˆ
′
q + 2
K∑
q 6=q′
γˆq(X
′WX)aq ,aq′ γˆ
′
q′
]−1( K∑
q=1
aqγˆq
)
,
(5.22)
where subscript aq denotes the matrix entry corresponding to the parameter estimate of the
q-th mediator, and aq, aq′ denotes the off-diagonal entry corresponding to the estimates of
the mediators, mq and mq′ . Under the null hypothesis, T
2 is distributed as a χ21, so the
critical values are chosen such that
α = PH0
(
T 2 > χ21,1−α
)
. (5.23)
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5.1.3.2 Product of Standardized Coefficients Test The null hypothesis for the PSC
significance test is H0 =
∑K
q=1 αqγq = 0 with test statistic
K∑
q=1
Vq =
K∑
q=1
(
aq
σaq
γˆq
σγˆq
)
. Using
the normal scale mixture theory from the previous chapter, we get that
K∑
q=1
Vq is distributed
according to a multivariate normal distribution with mean and variance:
E
(
K∑
q=1
Vq
)
=
K∑
q=1
(
αq
σαq
γq
σγq
)
(5.24)
(5.25)
Var
(
K∑
q=1
Vq
)
=
K∑
q=1
Var(Vq) + 2
K∑
q 6=q′
Cov(Vq,Vq′)
=
K∑
q=1
[(
z2aq +
(
αq
σαq
)2)
Σγq +
γq
σγq
γq
σγq
′
]
+2
K∑
q 6=q′
[
Cov
(
γˆq
σγˆq
,
γˆq′
σγˆq′
)(
|zaqzaq′ |+ |zaq |
(
αq′
σαq′
)
+ |zaq′ |
(
αq
σαq
))]
,
(5.26)
where |zaq | and |zaq′ | are folded normal random variables and z2aq is a chi squared random
variable.
5.1.4 Illustration on TORDIA data
The two significance tests – the d and PSC – were conducted on the TORDIA clinical trial
dataset with the original binary outcome of clinical response. As mentioned before, the
primary outcome was defined as the combination of the Clinical Global Impressions score
≤ 2 and a change in the Children’s Depression Rating Scale-Revised of ≥ 50%.
The three models in the multisite mediated moderation case ((5.1), (5.2), and (5.3)) were
conducted with 20 variables measured at baseline as potential mediators. There was overall
site moderation of treatment effect in (4.52) (p = 0.001) at the α = 0.05 significance level.
Since the second necessary equation did not change going from the continuous outcome to
71
the binary outcome case, treatment-by-site interaction persisted in the same two variables:
CBQA (p = 0.044) and TOTALD (p = 0.004).
After adjusting for the CBQA score, the magnitude of site moderation was reduced
(p = 0.006), which is a criteria for mediated moderation. Both tests were applied to the
data to see if the reductions in magnitudes were significant. Since the PSC test involves a
χ21 random variable, the expected value of 1 was chosen. The d test concluded that subject’s
CBQA score significantly explained the differing effect of CBT-MED therapy across the
six sites (p = 0.002). The Product of Standardized Coefficients test concluded that the
magnitude of interaction was significantly reduced (p < 0.001).
The magnitude of site moderation due to the adjustment for the TOTALD variable was
reduced, but not eliminated (p = 0.003). Both of the aforementioned tests were applied to
the data and only the PSC test concluded a significant reduction (pd = 0.173; pPSC < 0.001).
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6.0 DISCUSSION & FUTURE WORK
6.1 DISCUSSION
In summary, this dissertation has focused on the issue of site heterogeneity in both the
design and analysis stages of multisite clinical trials. While it is ideal to account for potential
sources at the design stage of a trial, this is only possible if there is statistical methodology
to identify them at the analysis end. The contribution of this dissertation is exactly that.
Using the concept of mediated moderation described by Muller et al. [39], three tests
popular in the mediation literature were extended to the multiple regression, ANOVA, and
logistic regression models used to analyze multisite clinical trials. The result is a battery
of significance tests to help explain treatment-by-site interaction. Each of the test were
developed in the two-treatment, two-site case and were extended to the J-site case.
The significance tests in the multiple regression and logistic regression cases were also
broadened to include K meditators. While the groundwork has already been laid, some care
is needed in the details of the PSC tests. This will be the focus of an upcoming paper.
Finally, once potential sources of site heterogeneity are chosen by the above tests, they
can inform the design for future clinical trials. Instead of basing sample size and power off
of a t-test or an ANOVA model, one can use the hierarchical linear models – (2.19) and
(2.20) – described in Chapter 2 with the potential sources as site-level covariates. One of the
conclusions mentioned in Spirito et al. was that multisite clinical trials should be powered
to detect site differences [47]. While the author agrees with this, it should be used if site
variability cannot be accounted for by methods such as HLMs mentioned above.
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6.2 FUTURE WORK
The author plans to investigate the following:
1. Study the details of the PSC and d tests (multiple regression and logistic regression)
with K mediators. Conduct simulation studies and apply to the TORDIA dataset.
2. A generalization of MMM to models in the generalized linear model framework.
3. Multisite clinical trials are not just limited to two treatments, so the extension of the
proposed MMM to a model with three or more treatments is needed.
4. All of the difference in coefficients test that have been outlined have treated the media-
tor(s) variable as fixed, whereas in the clinical trial setting the mediators vary. Account-
ing for this added variability will provide more accurate estimates of power.
5. Extend the MMM to the case where site is a random effect; explore different possi-
bilities for the random distribution such as the skew-t distribution as well as Bayesian
nonparametric approaches.
6. As in the two-site case, investigate the type I error inflation issue in the PSC tests.
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APPENDIX A
DERIVATION OF THE EQUALITY IN MMM
It is straightforward to show that (4.8) and (4.9) lead to (4.7) in the two-site, two-treatment
case. This leads to the useful equality seen in mediated moderation.
m = β10 + β11τ + β12s+ β13(τ ∗ s) + 1 (A.1)
y = α00 + α01τ + α02s+ α03(τ ∗ s) + α12m+ α13(m ∗ τ) + 2
= (α00 + α01τ) + (α02 + α03τ)s+ (α12 + α13τ)(β10 + β11τ)
+(α12 + α13τ)(β12 + β13τ)s+ (α12 + α13τ)1 + 2
= [(α00 + α01τ) + (α12 + α13τ)(β10 + β11τ)]
+ [(α02 + α03τ) + (α12 + α13τ)(β12 + β13τ)] s+ [(α12 + α13τ)1 + 2]
= [β00 + β01τ ] + [β02 + β03τ ] s+ 0. (A.2)
From this, we get
(β02 + β03τ) = (α02 + α03τ) + (α12 + α13τ)(β12 + β13τ)
(β02 + β03τ)− (α02 + α03τ) = (α12 + α13τ)(β12 + β13τ) (A.3)
which implies
β03 − α03 = α13β12 + α12β13. (A.4)
Muller et al. requires that at least one of the products on the right hand side of (A.4) be
non-zero [39]. So, by allowing the partial effect to not be moderated, no assumptions of
mediated moderation are violated.
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APPENDIX B
GAUSS-HERMITE QUADRATURE
If x ∼ N(µx, 1) and y ∼ N(µy, 1), then the pdf of p = xy is
f(p) = (2pi)−1
∫ ∞
−∞
1
y
e
−1
2 (
p
y
−µx)2e
−1
2
(y−µy)2dy. (B.1)
When µx = µy = 0, the above integral is approximated by a modified Bessel function of the
second kind [12]. Otherwise, Gauss-Hermite quadrature is one way of approximating the
integral such that ∫ ∞
−∞
e−x
2
f(x) ≈
n∑
i=1
w(xi)f(xi), (B.2)
where w(xi) is a weight function evaluated at the i-th root of a Hermite polynomial. The
total number of nodes, n = 32, was chosen based on how well the quadrature approximated
the modified Bessel function in the case where both parameters are null.
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APPENDIX C
CONDITIONAL MEAN OF Y IN THE K-MEDIATOR CASE
Let the joint distribution of the outcome variable, y, and the mediator variables, m1,. . .,mk,
be

y
m1
...
mk
 ∼ N


β00 + β01τ + β02s+ β03(τ ∗ s)
β10 + β11τ + β12s+ β13(τ ∗ s)
...
βk0 + βk1τ + βk2s+ βk3(τ ∗ s)
 ,

σ20 σ01 . . . σ0k
σ10 σ
2
1 . . . σ1k
...
...
. . .
...
σk0 σk1 . . . σ
2
k


.
If we partition y from the mediator variables such that the variance-covariance matrix is
Σym =
 σ20 Σ0m
Σm0 Σmm
 ,
then the conditional distribution of y is
(y|m1, . . . ,mk, τ, s) ∼ N
(
µy + Σ0mΣ
−1
mm(m− µm), σ20 − Σ0mΣ−1mmΣm0
)
.
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The term Σ0mΣ
−1
mm is referred to as the matrix of regression coefficients [24]. Then, we can
write the conditional mean as
µy|m1,...,mk,τ,s = µy +
[
α12 α22 . . . αk2
]

m1 − µm1
m2 − µm2
...
mk − µmk

= (β00 + β01τ + β02s+ β03(τ ∗ s)) +
k∑
i=1
αi2 (mi − βi0 + βi1τ + βi2s+ βi3(τ ∗ s))
=
(
β00 −
k∑
i=1
βi0αi2
)
+
(
β01 −
k∑
i=1
βi1αi2
)
τ +
(
β02 −
k∑
i=1
βi2αi2
)
s
+
(
β03 −
k∑
i=1
βi3αi2
)
(τ ∗ s).
(C.1)
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APPENDIX D
DERIVATION OF COVARIANCE OF INTERACTION EFFECT
ESTIMATES
In a 2-treatment, J-site, unbalanced ANOVA design with the following model, the J − 1
interaction effect estimates γˆij = y¯ij. − y¯i.. − y¯.j. + y¯... are correlated with each other.
Yijk = µ+ τi + sj + γij + ijk (D.1)
Let γˆij and γˆij′ be two estimates from the same treatment, but different sites. Then, the
covariance is as follows:
Cov(γˆij, γˆij′) = Cov(y¯ij. − y¯i.. − y¯.j. + y¯..., y¯ij′. − y¯i.. − y¯.j′. + y¯...)
= −Cov(y¯ij., y¯i..) + Cov(y¯ij., y¯...)− Cov(y¯i.., y¯ij′.) + Cov(y¯i.., y¯i..) + Cov(y¯i.., y¯.j′.)
−Cov(y¯i.., y¯...) + Cov(y¯.j., y¯i..)− Cov(y¯.j., y¯...) + Cov(y¯..., y¯ij′.)− Cov(y¯..., y¯i..)
−Cov(y¯..., y¯.j′.) + Cov(y¯..., y¯...)
= − σ
2
Jnij
+
σ2
IJnij
− σ
2
Jnij′
+
σ2
J2
J∑
j=1
(
1
nij
)
+
σ2
IJnij′
− σ
2
IJ2
J∑
j=1
(
1
nij
)
+
σ2
IJnij
− σ
2
I2J
I∑
i=1
(
1
nij
)
+
σ2
IJnij′
− σ
2
IJ2
J∑
j=1
(
1
nij
)
− σ
2
I2J
I∑
i=1
(
1
nij′
)
+
σ2
I2J2
I∑
i=1
J∑
j=1
(
1
nij
)
= σ2
[
1
4J2
2∑
i=1
J∑
j=1
(
1
nij
)
− 1
4J
2∑
i=1
(
1
nij
+
1
nij′
)]
. (D.2)
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The variance of a particular interaction effect estimate is
Var(γˆij) = Var(y¯ij. − y¯i.. − y¯.j. + y¯...)
=
σ2
nij
+
σ2
J2
J∑
j=1
(
1
nij
)
+
σ2
I2
I∑
i=1
(
1
nij
)
+
σ2
I2J2
I∑
i=1
J∑
j=1
(
1
nij
)
+2
[
− σ
2
Jnij
− σ
2
Inij
+
σ2
IJnij
+
σ2
IJnij
− σ
2
IJ2
J∑
j=1
(
1
nij
)
− σ
2
I2J
I∑
i=1
(
1
nij
)]
.
= σ2
[
J − 2
4J
2∑
i=1
(
1
nij
)
+
1
4J2
2∑
i=1
J∑
j=1
(
1
nij
)]
. (D.3)
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APPENDIX E
GENERALIZED INVERSE
Theorem 4. Let A be a p-by-1 dimensional vector, and let (AA′) be a square singular matrix
with generalized inverse (AA′)− defined in McCulloch & Searle [36]. Then, A′(AA′)−A = 1.
Proof. We know that
A′(AA′)−A = c, (E.1)
where c is a scalar. If we pre- and post-multiply by A and A′, respectively, we get
(AA′)(AA′)−(AA′) = AcA′. (E.2)
Because (AA′)− is a generalized inverse, then c = 1 must be true.
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